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Gene-environment interactions play a key role in how psychiatric
disorders manifest and develop. Psychiatric genetics researchers
are making progress in identifying genomic correlates of many
disorders. And recently, the field of genetics has given rise to a
technology that many claim will revolutionize the biological
sciences and propel the field into a transformative phase: the
powerful gene-editing tool known as CRISPR-Cas9. This Article
illustrates which psychiatric conditions are likely to make
attractive targets for CRISPR as the technology evolves and
CRISPR therapies become viable tools to manage or prevent
disorders in a clinical setting. We examine the potential scientific
and clinical challenges of applying CRISPR in the mental health
context, along with the regulatory, ethical, and legal issues that
might arise as a consequence of these applications.
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INTRODUCTION
Treating psychiatric disorders with the drugs and therapies
developed to date has proved challenging. Psychotropic medications
often aren’t effective for patients,1 who in turn have a hard time
committing to rigorous and slow-acting treatment regimens.2 But in
addition to being notoriously hard to treat, psychiatric disorders are
also well known for being highly heritable.3 As such, a number of
recent large-scale genetic studies have focused their efforts on
psychiatric disorders,4 and this innovative research has begun to
unravel the science behind important genes and causal pathways.5
Breakthroughs in genetics have made room for a potentially superior
treatment option: the future application of gene-editing technologies
for addressing the symptoms of psychiatric disorders.6
Ever since the elegant discovery of the double helix in 1953,7
scientists have looked for ways to manipulate and design DNA.8 As a
consequence, gene-editing tools have actually been around for some
time.9 Yet it wasn’t until the advent of “a simple, inexpensive, and
1. See Anita Kablinger, Treatment Resistance: Challenges and Solutions,
PSYCHIATRIC TIMES (Sept. 1, 2007), http://www.psychiatrictimes.com/articles/treatmentresistance-challenges-and-solutions [https://perma.cc/R6NZ-UJXR].
2. See, e.g., Annette Zygmunt et al., Interventions to Improve Medication Adherence
in Schizophrenia, 159 AM. J. PSYCHIATRY 1653, 1653 (2002) (“Rates of medication
nonadherence among outpatients with schizophrenia have been found to approach 50%
during the first year after hospital discharge. The actual rate of nonadherence may be even
higher . . . .” (footnotes omitted)).
3. Michael J. Gandal et al., The Road to Precision Psychiatry: Translating Genetics
into Disease Mechanisms, 19 NATURE NEUROSCIENCE 1397, 1397 (2016).
4. See id. (discussing “more recent, large-scale genome-wide studies” of psychiatric
diseases).
5. Id.
6. See Tom Ulrich, Gene Sifting for Gene Snipping: GWAS as a Source of Gene
Editing Targets, VECTOR (Oct. 29, 2015), https://vector.childrenshospital.org/2015/10/
gwas-as-a-source-of-gene-editing-targets/ [http://perma.cc/CT8P-GTF2]; see also Roni
Dengler, Major Mental Illnesses Unexpectedly Share Brain Gene Activity, Raising Hope for
Better Diagnostics and Therapies, SCIENCE (Feb. 8, 2018, 2:00 PM),
https://www.sciencemag.org/news/2018/02/major-mental-illnesses-unexpectedly-share-braingene-activity-raising-hope-better [https://perma.cc/EJ8D-D484].
7. See generally J. D. Watson & F. H. C. Crick, Molecular Structure of Nucleic Acids:
A Structure for Deoxyribose Nucleic Acid, 171 NATURE 737 (1953) (describing the
authors’ discovery of the structure of DNA).
8. See Brian Colwell, Biotechnology Timeline: Humans Have Manipulated Genes
Since the ‘Dawn of Civilization,’ GENETIC LITERACY PROJECT (July 18, 2017),
https://geneticliteracyproject.org/2017/07/18/biotechnology-timeline-humans-manipulatinggenes-since-dawn-civilization/ [http://perma.cc/NJ43-9XHM].
9. See Jennifer A. Doudna & Emmanuelle Charpentier, The New Frontier of
Genome Engineering with CRISPR-Cas9, 346 SCIENCE, no. 1258096, Nov. 28, 2014, at 1, 1,
2 fig.1.
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remarkably effective genome engineering method”—known as
CRISPR-Cas9 (“CRISPR”)10—that biology was propelled into a
transformative phase: CRISPR triggered a revolution.11
CRISPR stands for Clustered Regularly Interspaced Short
Palindromic Repeats12 and works like a pair of molecular scissors.13
Scientists can direct CRISPR to a specific spot along an individual’s
DNA and have the molecular scissors make cuts in the gene
sequence.14 Therapeutically relevant changes can then be inserted.15
As clinical trials using CRISPR systems to target specific conditions
are slated to start around the world, a debate has sparked on the legal
and ethical implications of CRISPR technology.16 Certainly, a
prudent look to the potential niches in psychiatry where CRISPR
systems may prove useful requires giving some attention to the legal
and ethical issues that might arise. This is particularly so given the
incendiary past of the American legal discourse on the intersection of
psychiatric disorders and genetic modification.17
This Article argues that while applications of CRISPR in
psychiatry may not be imminent, these applications are no longer
improbable hypotheticals. And where applications in psychiatry may
well exist in the near future, there are important legal and ethical
concerns that warrant careful consideration. This Article will proceed
in three parts. Part I serves as an overview of CRISPR technologies,
10. David Baltimore et al., A Prudent Path Forward for Genomic Engineering and
Germline Gene Modification, 348 SCIENCE 36, 36 (2015). Although the terms CRISPRCas9 and CRISPR are used interchangeably, CRISPR-Cas9 is a system that incorporates
“CRISPR,” which are the repeat sequences frequently observed in single-celled
organisms. See Questions and Answers About CRISPR, BROAD INST.,
https://www.broadinstitute.org/what-broad/areas-focus/project-spotlight/questions-andanswers-about-crispr [https://perma.cc/LM4S-MG92].
11. See Doudna & Charpentier, supra note 9, at 1.
12. DAVID P. CLARK & NANETTE J. PAZDERNIK, MOLECULAR BIOLOGY 573 (2d ed.
2013).
13. See Andrea Ramirez, Editing the Book of Life with Molecular Scissors, NIH:
NAT’L HUM. GENOME RES. INST. (Apr. 3, 2013), https://www.genome.gov/27553432/
editing-the-book-of-life-with-molecular-scissors/ [http://perma.cc/R2HJ-5R77]. The Cas9
in CRISPR-Cas9 refers to certain genes that are associated with important repeated
sequences, known as Cas genes. Cas genes, including Cas9 genes, produce the nuclease
scissor proteins that scientists have used to design genome-editing tools that cut into
human DNA. This is explained in more detail below. See infra Section I.A.
14. See Ramirez, supra note 13.
15. See id.
16. See, e.g., E. Rodriguez, Ethical Issues in Genome Editing Using CRISPR/Cas9
System, 7 J. CLINICAL RES. & BIOETHICS, no. 1000266, Mar. 24, 2016, at 1, 2–3.
17. For example, in Buck v. Bell, 274 U.S. 200 (1927), Justice Holmes concluded with
the unfortunate remark: “Three generations of imbeciles are enough.” Id. at 207. For a
short description of the facts and holding of Buck, see infra note 150.
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skimming the surface of the relevant science, placing CRISPR
systems in their historical context, and evaluating regulatory
frameworks currently in place. Part II focuses on CRISPR and its
potential uses in psychiatry, identifying where the technology might
be most immediately applied. Part III addresses the legal, ethical, and
policy challenges that arise from the application of CRISPR in a
psychiatric context.
I. CRISPR TECHNOLOGIES: AN OVERVIEW
A. A Brief Introduction to the Science
DNA serves as a blueprint for all of an organism’s characteristics
and traits after birth: it is the instructions—a set of plans—for
building a body.18 A chain of DNA is made up of building blocks,
small molecules called nucleotides.19 These nucleotides string
together to form different sequences that code for certain messages,
and these different message sequences are referred to as genes.20 The
sum total of an individual’s DNA—the collection of all of a person’s
genes—is referred to as a genome.21 Scientists have been modifying
organisms’ genomes for some time, and recently these technologies
have become highly effective.22
To understand gene-editing technologies, it’s helpful to have a
grasp on how scientists cut and repair DNA. Nuclease is a protein23
18. RICHARD DAWKINS, THE SELFISH GENE 23 (1976). Although a simple way to
understand DNA, if taken literally this analogy is not precise. Genes alone do not serve as
a blueprint, but rather the genetic blueprint has downstream effects, such as the
interactions between different genes, that ultimately dictate how a body develops. See
Bora Zivkovic, BIO101—From Genes to Traits: How Genotype Affects Phenotype, SCI.
AM.: BLOG AROUND THE CLOCK (Sept. 17, 2011), https://blogs.scientificamerican.com/
a-blog-around-the-clock/bio101-from-genes-to-traits-how-genotype-affects-phenotype
[http://perma.cc/8CN4-4FRH].
19. DAWKINS, supra note 18, at 23. There are only four different nucleotides that
make up DNA: Adenine, Thymine, Cytosine, and Guanine. See id. For an accessible
explanation of the building blocks of DNA, see Bozeman Science, What Is DNA?,
YOUTUBE (Dec. 7, 2011), https://www.youtube.com/watch?v=q6PP-C4udkA
[http://perma.cc/Q8JF-4H5N].
20. See DNA, Genes and Chromosomes, U. LEICESTER, https://www2.le.ac.uk/projects/
vgec/highereducation/topics/dna-genes-chromosomes [https://perma.cc/7YPE-B5CE].
21. What Is a Genome?, NIH: GENETICS HOME REFERENCE, https://ghr.nlm.nih.gov/
primer/hgp/genome [http://perma.cc/B5PJ-54R5] (last updated Apr. 30, 2019).
22. See Baltimore et al., supra note 10, at 36.
23. All proteins are the product of gene sequences. For a quick and accessible
explanation of protein synthesis, see Yourgenome, From DNA to Protein—3D, YOUTUBE
(Jan. 7, 2015), https://www.youtube.com/watch?v=gG7uCskUOrA [http://perma.cc/5QY6T3GQ].

97 N.C. L. REV. 1359 (2019)

1364

NORTH CAROLINA LAW REVIEW

[Vol. 97

that functions like the equivalent of molecular scissors.24 Scientists
can direct nuclease scissors to an exact spot among the billions of
nucleotides making up a DNA sequence, and the nuclease will cut out
a part of the DNA chain.25 This cut can be repaired by either allowing
the loose ends to join back together or by having the CRISPR system
insert a new designer DNA segment to replace the piece cut out by
the nuclease.26
Thanks to advances in DNA sequencing and genome-wide
association studies (“GWAS”),27 scientists now have more
information about which DNA segments influence the development
of disease.28 The information gathered by GWAS can be applied
through CRISPR technologies. As previously noted, CRISPR stands
for Clustered Regularly Interspaced Short Palindromic Repeats.29
These repeats are distinct sequences of nucleotides, frequently
observed in the DNA of single-celled organisms like bacteria.30
Certain genes are associated with these repeated sequences, and these
genes are known as Cas genes.31 Cas genes, including the Cas9 gene,
produce the nuclease scissor proteins (“Cas proteins”) that scientists
use to design genome-editing tools that cut into human DNA.32
The Cas protein is one of two main components making up an
engineered CRISPR system.33 The second is known as a guide RNA.
A guide RNA is a short synthetic RNA sequence that includes a
24. See Ramirez, supra note 13.
25. Id. We have simplified the description of the process so as to make it more
accessible to a broader audience. The science behind CRISPR’s mechanisms is much more
complicated, and the excision language we have employed is far too cursory to adequately
convey the nuances involved. Most of the time, CRISPR nucleases either make a doublestranded break or a nick in one strand. An excision needs two breaks, and even then, the
excision really isn’t a result of the molecular scissors: it’s the DNA repair machinery
deleting the intervening DNA. For a detailed explanation of CRISPR mechanisms as
currently understood, see generally Samuel H. Sternberg & Jennifer A. Doudna,
Expanding the Biologist’s Toolkit with CRISPR-Cas9, 58 MOLECULAR CELL 568 (2015).
26. Ramirez, supra note 13.
27. In GWAS, scientists look at the genomes of a large number of afflicted individuals
and find small variations that occur repeatedly in the genes of these individuals but don’t
appear in the genomes of nonafflicted individuals. See Genome-Wide Association Studies
Fact Sheet, NIH: NAT’L HUM. GENOME RES. INST. (Aug. 27, 2015),
https://www.genome.gov/20019523/ [http://perma.cc/DQ5J-ABG5].
28. See Baltimore et al., supra note 10, at 36.
29. CLARK & PAZDERNIK, supra note 12, at 573.
30. Id.
31. Philippe Horvath & Rodolphe Barrangou, CRISPR/Cas, the Immune System of
Bacteria and Archaea, 327 SCIENCE 167, 167 (2010).
32. See id.
33. CRISPR Guide, ADDGENE, https://www.addgene.org/crispr/guide/ [http://perma.cc/
X6A6-93AL].
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sequence necessary for Cas-binding—a scaffold sequence—and a
user-defined sequence that directs the CRISPR system to its genomic
target.34 This means one can change the genomic target of the Cas
protein by simply changing the guide RNA’s protein sequence.
Although CRISPR is the most effective and accessible method of
genetic engineering available today, CRISPR was not the first geneediting tool developed.35 Other technologies targeting similar goals
have been around for several decades.36 Yet CRISPR is being
championed as a technique that promises to revolutionize medicine
where previous attempts have failed.37 Technologies such as zinc
finger nucleases (“ZFNs”), Transcription Activator-Like Effector
Nucleases (“TALENs”), and mega-nucleases have seen some
success.38 But these technologies have yet to alter the landscape of
modern medicine in the way CRISPR proponents have promised.39
B.

CRISPR’s Precursors: Previous Attempts at Achieving the Same
Functionality

Gene-editing tools that predate CRISPR all share the same
mechanism of action—they are all nucleases that create breaks at
specific locations in DNA.40 The most important characteristic of a
nuclease, as it relates to medical gene editing, is the programmability
of the molecular scissors41—that is, the relative ease with which
scientists can design and produce a molecular scissor that will cut the

34. Id. “RNA is one of the three major biological macromolecules that are essential
for all known forms of life (along with DNA and proteins).” What Is RNA?, RNA SOC’Y,
https://www.rnasociety.org/about/what-is-rna/ [http://perma.cc/6FYH-YHP6].
35. See Doudna & Charpentier, supra note 9, at 1. In essence, “gene editing” connotes
the use of a tool that can alter or even correct DNA and has effectively come to succeed
the term “genetic engineering.” John J. Mulvihill et al., Ethical Issues of CRISPR
Technology and Gene Editing Through the Lens of Solidarity, 122 BRIT. MED. BULL. 17,
18 (2017).
36. See Doudna & Charpentier, supra note 9, at 1.
37. See, e.g., Jacob S. Sherkow, CRISPR, Patents, and Public Health, 90 YALE J.
BIOLOGY & MED. 667, 667 (2017) (“CRISPR has the potential to revolutionize
medicine.”).
38. See Doudna & Charpentier, supra note 9, at 1.
39. See id.
40. See Rasmus O. Bak, Natalia Gomez-Ospina & Matthew H. Porteus, Gene Editing
on Center Stage, 34 TRENDS GENETICS 600, 600 (2018).
41. See Tuhin Kumar Guha, Alvan Wai & Georg Hausner, Programmable Genome
Editing Tools and Their Regulation for Efficient Genome Engineering, 15
COMPUTATIONAL & STRUCTURAL BIOTECHNOLOGY J. 146, 147 (2017) (addressing the
importance of programmability, given that “[o]ne crucial concern when applying these
genetic editing tools is the potential of cleavage at non-targeted sites,” which “can be
lethal or generate undesirable mutations”).
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DNA at the desired location.42 To place the utility of CRISPR in
some context, two of CRISPR’s precursors are described here in
detail: ZFNs and TALENs.
ZFNs are one of the earliest popularized attempts at site-specific
nuclease targeting.43 Researchers combine the scissor component
found in one protein, nonspecific FokI endonuclease domain,44 and
the DNA-targeting component of another protein, a zinc finger
protein, to create programmable DNA scissors.45 Zinc fingers get
their name from a particular sequence of amino acids. When these
amino acids come together with a zinc ion, they can bind to a specific
sequence of DNA three basepairs long.46 To target a longer DNA
segment, scientists put more zinc fingers together. For example,
targeting eighteen basepairs of DNA would require six zinc fingers.
In order to target any particular DNA sequence, researchers had
to develop a zinc finger for each of the sixty-four possible DNA
basepair triplets.47 Because of these complexities and others, creation
of ZFN constructs has proven difficult.48 Despite the associated
challenges, ZFNs are some of the oldest and most studied designer
nucleases available and are the focus of recent clinical trials.49
TALENs use the same architecture as ZFNs. With TALENs, the
scissor component is fused with a different type of DNA-binding
component: the transcription activator-like effector (“TALE”).50
These DNA-binding elements are different from zinc fingers in that
their DNA-binding domains each recognize a single basepair of

42. See id.; see also Srinivasan Chandrasegaran & Jeff Smith, Chimeric Restriction
Enzymes: What Is Next?, 380 BIOLOGICAL CHEMISTRY 841, 847 (1999) (“Many of the
difficulties associated with gene therapy are likely to be overcome if one could insert the
corrected version of the mutation at the precise location of the genetic defect within the
genome . . . . Current gene therapy vectors lack the requisite sequence specificity necessary
for the targeted correction of the defective site within the genome.”).
43. See James Gallagher, First Gene-Editing in Human Body Attempt, BBC NEWS
(Nov. 16, 2017), https://www.bbc.com/news/health-42009929 [http://perma.cc/C34W-P93G]
(discussing the first attempt at gene editing in human cells, which was done using ZFNs).
44. See Chandrasegaran & Smith, supra note 42, at 843.
45. Id. at 844.
46. Id. at 843 (“[E]ach finger interacts with a base pair triplet within the DNA
substrates.”).
47. See id.
48. See Doudna & Charpentier, supra note 9, at 1.
49. See, e.g., Ascending Dose Study of Genome Editing by Zinc Finger Nuclease
Therapeutic SB-FIX in Subjects with Severe Hemophilia B, CLINICALTRIALS.GOV,
https://clinicaltrials.gov/ct2/show/NCT02695160 [http://perma.cc/CK2K-PTXX] (last updated
Feb. 12, 2019).
50. Michelle Christian et al., Targeting DNA Double-Strand Breaks with TAL
Effector Nucleases, 186 GENETICS 757, 757 (2010).
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DNA,51 as opposed to the zinc fingers’ three basepairs. Thus, it is
simpler to design a TALEN that recognizes a specific eighteenbasepair sequence of DNA. Due to the nature of each DNA-binding
element, however, TALENs are difficult to build using available
molecular biology techniques—a technical hurdle that has stifled
TALEN adoption.52
In contrast, the CRISPR system provides a high degree of DNA
sequence specificity and programmability.53 The relative ease of
design and production of the CRISPR components is the primary
feature that separates this system from its precursors and has caused a
renewed interest and enthusiasm in medical gene editing.
C.

The Legal and Ethical Legacy of Previous Attempts and Their
Implications

Because CRISPR is not the first attempt at gene editing, at first
blush, it seems as though many of the ethical issues raised by CRISPR
are equivalent to those that surfaced several decades ago.54 Given the
previous attempts at achieving therapeutic outcomes by means of
gene editing, a vast body of literature exists addressing important
legal and ethical issues that arise in the context of genetic
modification.55 As such, a framework of general principles governing
the rules for human gene editing already exists. This framework is
worth considering as a foundation to any dialogue on the ethical
implications of new gene-editing technologies.56
Early gene-therapy clinical research resulted in serious adverse
events.57 But it wasn’t until the death of Jesse Gelsinger, a young
51. See id.
52. See Thomas Gaj, Charles A. Gersbach & Carlos F. Barbas III, ZFN, TALEN, and
CRISPR/Cas-Based Methods for Genome Engineering, 31 TRENDS BIOTECHNOLOGY 397,
399 (2013).
53. See id. at 402.
54. See, e.g., Mulvihill et al., supra note 35, at 17–18 (“We see no new ethical issues,
compared with gene therapy and genetic engineering in general, apart from the explosive
rate of findings.”).
55. See Eric T. Juengst, Crowdsourcing the Moral Limits of Human Gene Editing?,
HASTINGS CTR. REP., May–June 2017, at 15, 15 (“On the whole, [the Committee on
Human Gene Editing’s] report [authored in response to the success of CRISPR/Cas9
systems] builds reassuringly on what has come before and underscores that there are
precedents, arguments, and well-accepted general principles to turn to in framing the
‘rules’ for human gene editing.”).
56. See id. (“[T]he report also provides a great primer on the science and regulatory
landscape of gene editing, and it reviews some of the key points from the debates over
human germ-line and enhancement interventions to date.”).
57. See Theodore Friedmann, Principles for Human Gene Therapy Studies, 287
SCIENCE 2163, 2163 (2000). Most notable is the death of eighteen-year-old Jesse Gelsinger
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patient enrolled in a gene-therapy clinical trial, that a great number of
these adverse events became public.58 Important, though not unique
to gene editing, is the fact that preclinical data cannot reveal all
possible adverse outcomes. And so, as with any highly experimental
treatment involving severely ill patients, human trials yield
unexpected and unintended results.59 The need for a more thorough
understanding of the science and effects of the applications of gene
editing in humans was criticized as a limitation of early technologies.60
It remains a concern of the scientific community in the face of
CRISPR’s clinical applications.
It is critical that safety information regarding new technologies is
made readily available.61 As early mishaps in gene-therapy clinical
trials have taught us, the lack of public awareness of safety problems
impairs not only the ability of researchers to inform subjects of
potential risks but also their ability to design safe studies. That is,
when clinical research sites fail to report adverse events, other
research sites cannot adjust their protocols and informed consent
who had been diagnosed with ornithine transcarbamylase deficiency. Id. Gelsinger is
thought to have died as a result of an experimental gene-therapy clinical trial. Id. For a
poignant account of Gelsinger’s death, see generally Paul L. Gelsinger, Uninformed
Consent: The Case of Jesse Gelsinger, in LAW AND ETHICS IN BIOMEDICAL RESEARCH:
REGULATION, CONFLICT OF INTEREST, AND LIABILITY 12 (Trudo Lemmens & Duff R.
Waring eds., 2006).
58. LORI B. ANDREWS, MAXWELL J. MEHLMAN & MARK A. ROTHSTEIN,
GENETICS: ETHICS, LAW AND POLICY 405–06 (2002). Due to a long-standing Food and
Drug Administration (“FDA”) policy stating that adverse events are considered trade
secrets and thereby need not be disclosed to the public, the adverse events that had been
reported to the FDA were never disclosed. Id.; see also 21 C.F.R. §§ 601.50–.51 (2018). But
see id. § 601.50(c) (stating that “[n]otwithstanding the provisions of § 601.51, the [FDA]
shall disclose upon request to an individual on whom an investigational biological product
has been used a copy of any adverse reaction report relating to such use”). And since the
NIH did have a policy to make public adverse events reported to the agency, investigators
failed to report their findings. ANDREWS ET AL., supra, at 406. Only thirty-nine serious
adverse events had been reported to the NIH before Gelsinger’s death. Id. Six hundred
ninety-one reports streamed in afterward. Id.
59. See id. It is also important to note that scientists’ depth of understanding of the
pharmacokinetics and mechanisms for gene-editing technologies does not match the
understanding that usually accompanies a potential new drug. Id. That is, scientists usually
know a lot more about a new pharmacological agent up for FDA approval than they know
about the mechanisms at play when gene-editing technologies are applied. There is also
the possibility that modifications intended to target somatic cells may have unintended
effects on the germline, which poses implications for how to manage enrolling patients of
reproductive age into clinical trials. See Nancy M.P. King, Accident & Desire: Inadvertent
Germline Effects in Clinical Research, HASTINGS CTR. REP., Mar.–Apr. 2003, at 23, 23.
60. See generally Friedmann, supra note 57 (discussing the lessons learned from
adverse gene therapy studies and “reexamin[ing] the principles that constitute the
foundation of clinical research in gene therapy”).
61. See ANDREWS ET AL., supra note 58, at 406.
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procedures based on the new information and may overlook
important patterns in their patients’ reported side effects. Likewise,
patients cannot have a full understanding of the risks and benefits the
research entails.62 To safeguard against information deficiencies,
commentators have proposed optimizing informed consent
procedures to protect patient interests.63 Additionally, they have
suggested that the monitoring of clinical trials needs improvement.64
To be sure, previous attempts at genetic modification have
generally underdelivered on lofty promises of profound benefits.65
CRISPR technology, however, may finally find its way into the
successful clinical applications that eluded all others. CRISPR is
different: it’s cheaper, easier to use, and developing at a much faster
pace than its technological predecessors.66 Also, its mechanism
promises results that sound highly desirable: a simple process that can
precisely target and cut out an undesirable mutation, replace it with a
“normal” DNA sequence, and then zip the repaired DNA back up
again.67 But the assumption that CRISPR can be used therapeutically
oversimplifies and understates the complexities of translating basic
scientific research into a clinical setting. As before, part of the ethical
challenge accompanying the introduction of CRISPR technologies
into a clinical setting is divorcing hype from reality.68
We begin by identifying those areas of psychiatry in which
CRISPR may find more immediate application and go on to address
the legal and ethical implications unique to the applications of
62. See id. Incidentally, the FDA proposed a regulation that would have amended the
biological licensing application and provided for the public disclosure of investigational
new drug safety reports. See Availability for Public Disclosure and Submission to FDA for
Public Disclosure of Certain Data and Information Related to Human Gene Therapy or
Xenotransplantation, 66 Fed. Reg. 4688, 4688 (proposed Jan. 18, 2001). But the FDA
eventually withdrew the proposed rule. See Withdrawal of Two Proposed Rules, 81 Fed.
Reg. 79,400, 79,400 (Nov. 14, 2016) (withdrawing the proposed regulation because the
FDA believed the concerns were outdated).
63. See, e.g., Friedmann, supra note 57, at 2163, 2165; see also Gail E. Henderson et
al., Therapeutic Misconception in Early Phase Gene Transfer Trials, 62 SOC. SCI. & MED.
239, 250–52 (2006) (proposing a novel method to manage the expectations of patients
enrolling in early phase clinical trials and calling for investigators to describe the potential
benefits of these trials realistically to patients who viewed them as their last hope).
64. Friedmann, supra note 57, at 2165. One of the most egregious findings of the
FDA’s investigations of early gene therapy trials was the fact that the investigators had
serious and undisclosed conflicts of interest. See ANDREWS ET AL., supra note 58, at 405.
They owned stock in the biotechnology company trying to monetize the gene therapy. Id.
65. See Juengst, supra note 55, at 15.
66. Evita V. Grant, FDA Regulation of Clinical Applications of CRISPR-CAS GeneEditing Technology, 71 FOOD & DRUG L.J. 608, 632 (2016).
67. See supra Section I.A.
68. Mulvihill et al., supra note 35, at 19.
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CRISPR in psychiatry.69 Certainly, clinical applications of CRISPR
technology for psychiatric disorders are ultimately distant goals.70
After all, even if scientists are successful at modifying every gene
potentially associated with a psychiatric disorder, the intervention’s
potential effects are still unknown. For example, even if genomes
could be successfully edited to express the relevant proteins in
nonpathogenic form, the impact of having lived years with pathogenic
variants could have long-term downstream effects on the brain that
limit the effectiveness of CRISPR interventions for reducing
psychiatric symptoms.71 Nevertheless, engaging in dialogue on the
potential ethical and legal issues that might arise as these applications
approach clinical realization is essential for preparing the scientific
community to responsibly engage in the execution of CRISPR
applications. This is especially true in the field of psychiatry, given the
egregious history that exists at the intersection of psychiatry and the
law.72
D. Regulating CRISPR: The Current Framework’s Structure and
Consequences
The enthusiasm for CRISPR and its possible applications are
accompanied by questions as to how and to what extent the testing of
CRISPR systems in humans should be regulated.73 The Food and
Drug Administration (“FDA”), housed within the Department of
Health and Human Services (“DHHS”), is tasked with regulating
technologies relating to drugs and biological products in accordance
69. See infra Section II.B, Part III.
70. See infra Part II.
71. See infra notes 163–64 and accompanying text.
72. See infra Section III.B.2.
73. Robert M. Califf & Ritu Nalubola, FDA, FDA’s Science-Based Approach to
Genome Edited Products, FDA VOICE (Jan. 18, 2017), https://perma.cc/X936-U9JJ,
reprinted in Robert M. Califf & Ritu Nalubola, FDA’s Science-Based Approach to
Genome Edited Products, CHECK ORPHAN (Jan. 19, 2017), http://www.checkorphan.org/
news/fda2019s-science-based-approach-to-genome-edited-products [https://perma.cc/C7H3QDG7]; see also Preetika Rana, Amy Dockser Marcus & Wenxin Fan, China,
Unhampered by Rules, Races Ahead in Gene-Editing Trials, WALL ST. J. (Jan. 21, 2018,
2:19 PM), https://www.wsj.com/articles/china-unhampered-by-rules-races-ahead-in-geneediting-trials-1516562360 [https://perma.cc/WZ4S-GQ3Q (dark archive)]. Clinical trials
using CRISPR technologies are already underway in China, where the regulation and
oversight of clinical trials is different than the oversight in the United States. See Rana et
al., supra. Chinese clinicians stated that the potential benefit of CRISPR technologies
outweigh the benefit of more rigorous regulations: “Dr. Wu says he sees saving patients’
lives as paramount. He began by testing [CRISPR] on three patients and has modified
genes of more than a dozen. He says he is planning other trials with lung-cancer and
pancreatic-cancer patients.” Id.
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with the Federal Food, Drug, and Cosmetic Act of 1938,74 the Public
Health Service Act of 1944,75 and their subsequent amendments.76 As
with previous gene-editing tools, the FDA treats CRISPR in
accordance with its 1998 guidance on human somatic cell therapy and
gene therapy.77 Gene-therapy products, including CRISPR systems,
are currently regulated under the existing framework for biological
products.78 This means that CRISPR interventions have to undergo
testing via clinical trials before obtaining FDA approval for clinical
use.79
Once a CRISPR compound is developed and information about
its potential toxic effects is gathered via animal research, the sponsor
of the CRISPR compound must submit an Investigational New Drug
74. Federal Food, Drug, and Cosmetic Act, ch. 675, 52 Stat. 1040 (1938) (codified as
amended at 21 U.S.C. §§ 301–399(f) (2012)).
75. Public Health Service Act, ch. 373, 58 Stat. 682 (1944) (codified as amended at 42
U.S.C. §§ 201–300mm-61 (2012)); see also Statement of Policy for Regulating
Biotechnology Products, 49 Fed. Reg. 50,878, 50,878 (Dec. 31, 1984) (“The administrative
review of products using biotechnology is based on the intended use of each product on a
case-by-case basis.”). The proposed FDA regulation providing for the public disclosure of
Investigational New Drug (“IND”) safety reports for gene-therapy studies “marked the
first time that the FDA proposed to adopt formal regulations specifically dealing with
gene therapy” as separate from biotechnology more generally. ANDREWS ET AL., supra
note 58, at 406.
76. Important for our purposes, FDA oversight covers public and private institutions.
As Grant noted in her piece:
This is especially important with respect to CRISPR-Cas technology, which is easy
to use, widely available, and inexpensive. Private institutions such as fertility
clinics, are capable of using it without reliance on federal funding. Hence, federal
legislation may be ineffective if it prohibits only funding of specific research
activities. FDA authority over private institutions allow[s] it to regulate the private
sector in situations in which federal legislative prohibitions do not explicitly
address.
See Grant, supra note 66, at 632.
77. See generally CTR. FOR BIOLOGICS EVALUATION & RESEARCH, FDA,
GUIDANCE FOR INDUSTRY: GUIDANCE FOR HUMAN SOMATIC CELL THERAPY AND
GENE THERAPY (1998), https://www.fda.gov/downloads/BiologicsBloodVaccines/
GuidanceComplianceRegulatoryInformation/Guidances/CellularandGeneTherapy/
ucm081670.pdf [https://perma.cc/M4W3-9VGH] (intending to “provide manufacturers
with current information regarding regulatory concerns for production, quality control
testing, and administration of recombinant vectors for gene therapy; and of preclinical
testing of both cellular therapies and vectors”). The guidance defines a gene therapy as “a
medical intervention based on modification of the genetic material of living cells. Cells
may be modified ex vivo for subsequent administration to humans, or may be altered in
vivo by gene therapy given directly to the subject.” Id. at 3.
78. Id. at 4 (“IND applications for somatic cell and gene therapies should follow the
same format and contain the same sections as IND’s for any investigational biological
product, as described in 21 CFR 312.23.”).
79. See id. at 23.
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(“IND”) application to the FDA.80 An IND application includes
information about the results of initial testing, the compound’s
composition and manufacturing, and a plan for how the sponsor
intends to test the effects of the CRISPR compound on humans.81
As described above, the guide RNA is one of the two main
components of an engineered CRISPR system.82 The guide RNA
component of the CRISPR system directs the system to its genomic
target. Because a particular guide RNA is needed for a CRISPR
system to reach a particular target, each system is theoretically useful
for a very limited purpose. As such, FDA approval is sought—not for
a generic CRISPR treatment applicable to all CRISPR systems,
regardless of which guide RNA they contain, but rather for a discrete
and specific CRISPR system.83
After the FDA determines that the proposed study will not place
human subjects under unreasonable risk of harm, the CRISPR system
must go through three stages of clinical trials.84 First, the CRISPR
80. See The Drug Development Process, Step 3: Clinical Research, FDA (Jan. 4, 2018),
https://www.fda.gov/ForPatients/Approvals/Drugs/ucm405622.htm [https://perma.cc/36XJTKLC].
81. See id.
82. See supra notes 33–34 and accompanying text.
83. See The Drug Development Process, Step 3: Clinical Research, supra note 80. The
fact that CRISPR systems composed of different guide RNAs have to be approved by the
FDA independently has important consequences for potential off-label uses. Historically,
the FDA has lacked the authority to regulate the practice of medicine. See, e.g., Chaney v.
Heckler, 718 F.2d 1174, 1179 (D.C. Cir. 1983) (noting that the legislative history of the
Federal Food, Drug, and Cosmetic Act reflects congressional intent to prohibit the FDA
from regulating the practice of medicine), rev’d on other grounds, 470 U.S. 821 (1985);
David A. Kessler, The Regulation of Investigational Drugs, 320 NEW ENG. J. MED. 281,
285 (1989). The agency itself accepted this view. See Legal Status of Approved Labeling
for Prescription Drugs; Prescribing for Uses Unapproved by the Food and Drug
Administration, 37 Fed. Reg. 16,503, 16,504 (Aug. 15, 1972) (“[I]t is clear that Congress
did not intend the [FDA] to regulate or interfere with the practice of medicine . . . .”). It’s
the agency’s lack of authority over the practice of medicine that allows physicians to
prescribe drugs for uses that the agency has not approved without violating federal law.
See Kessler, supra, at 285. For example, the FDA approved ketamine for the treatment of
pain in the early 1970s. See Gigen Mammoser, Ketamine Is Creating a New Wave of Drugs
to Treat Depression, HEALTHLINE (June 13, 2018), https://www.healthline.com/healthnews/ketamine-creating-wave-of-drugs-to-treat-depression#1 [https://perma.cc/JQ5SAM7Z]. But it wasn’t until the year 2000 that ketamine’s efficacy as an antidepressant was
discovered. Id. Once early reports of ketamine’s efficacy in treating depression surfaced,
doctors began prescribing ketamine infusions to patients off-label. Id. This was before the
FDA approved the drug for use as an antidepressant and, consequently, before clinical
trials were able to uncover important safety and efficacy data. Id. Given that a CRISPR
system containing a particular guide RNA is designed for a very specific target, off-label
uses would be severely limited.
84. See What Are the Types of Clinical Research? (Jan. 4, 2018), FDA,
https://www.fda.gov/ForPatients/ClinicalTrials/Types/default.htm [https://perma.cc/V8PY-
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system must undergo Phase I trials. Phase I trials are conducted on
healthy human volunteers.85 During Phase II trials, investigators
collect data on whether the CRISPR system actually works as
intended.86 Those enrolled in Phase II trials have been diagnosed with
the condition the CRISPR system intends to treat.87 Finally, largescale Phase III studies are conducted. During these trials, between
300 and 3000 subjects diagnosed with the target condition are
enrolled to gather more robust data on safety and effectiveness.88
Only after all of those hurdles are successfully cleared will a CRISPR
system obtain FDA approval for use in a clinical setting.
Previous attempts at developing clinical applications for geneediting technologies drew critiques of the schemes implemented to
regulate the drug approval process.89 Commentators, reflecting on the
early rounds of clinical trials researching gene-editing therapies,
noted that the monitoring of clinical trials needs improvement—
namely, more public disclosure and close collaboration between
public regulatory agencies and specialized advisory boards.90 These
and other concerns remain valid in the face of upcoming CRISPR
clinical trials.91
E48A] (noting that there are four phases of FDA trials but explaining that phase IV trials
are “[p]ost-marketing studies, which are conducted after a treatment is approved for use
by the FDA” (emphasis added)).
85. See The Drug Development Process, Step 3: Clinical Research, supra note 80. The
number of people enrolled in phase I trials varies but usually falls between twenty and one
hundred subjects. Id. The goal of this phase is to understand the most frequent side effects
and the system’s kinetics. Id.
86. Id. Phase II trials are placebo controlled, meaning some people who enter the trial
receive treatment with the CRISPR system while others do not. Safety and short-term side
effects are also evaluated. See, e.g., A Phase 2, Randomized, Placebo-Controlled,
Multicenter Study to Investigate the Efficacy and Safety of Apremilast (CC-10004) for
Treatment of Subjects with Active Ulcerative Colitis, CROHN’S & COLITIS FOUND.,
http://www.crohnscolitisfoundation.org/research/participate-in-research/find-studies-andclinical-trials/pda-study/Apremilast/a-phase-2-randomized-1.html [https://perma.cc/T77CGWZM].
87. The Drug Development Process, Step 3: Clinical Research, supra note 80.
88. Id.; see also Eva Andermann et al., Psychiatric and Cognitive Adverse Events: A
Pooled Analysis of Three Phase III Trials of Adjunctive Eslicarbazepine Acetate for
Partial-Onset Seizures, 82 EPILEPSY & BEHAV. 119, 121 (2018) (illustrating that the
number of patients enrolled into phase III trials is often in the hundreds).
89. See Friedmann, supra note 57, at 2165.
90. Id.; see also Grant, supra note 66, at 617 (“[The] FDA was slow to answer the call
for regulation of . . . gene therapy.”).
91. Recently, the FDA paused a CRISPR clinical trial slated to start in the United
States and asked for more information to be included on the sponsor’s IND application.
See Rich Haridy, FDA Hits Pause on One of the First US Human Clinical Trials to Use
CRISPR, NEW ATLAS (May 31, 2018), https://newatlas.com/us-crispr-human-trial-holdfda/54862/ [https://perma.cc/8N4W-S3E9].
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II. THE STATUS OF CRISPR FOR TREATING OR PREVENTING
PSYCHIATRIC CONDITIONS
Concededly, none of the clinical trials applying CRISPR
technologies slated to start in either the United States or abroad
involve applications to psychiatric disorders. While advances in
neuroscience over the past few decades have been tremendous, the
field itself is still rather young. And clinical translations of
neuroscience research into psychiatry have proven challenging.92
CRISPR, however, offers unique insights into the underlying biology
of psychiatric disorders and may have an important and imminent
role to play in developing therapies for a particular subset of
psychiatric conditions.
A. Review of Current Research in CRISPR Clinical Applications
As of today, CRISPR systems have been successfully used to
induce genetic modifications in a number of different species,
including rats,93 mice,94 pigs,95 nonhuman primates,96 and human cell
lines.97 But beyond CRISPR’s successful modification of genes,
experiments have recently confirmed that CRISPR technology can
actually be used in the treatment of inherited diseases. CRISPRinduced modifications now have a targeted purpose and are used to
achieve desired results. For example, CRISPR has successfully
reintroduced normally functioning genes into the genome of a live
animal, leading to the improvement of muscle function.98 Similarly,
CRISPR has been used to enhance liver function and induce changes

92. See John Horgan, The Brain: The Final Frontier of Science, GLOBE & MAIL (Mar.
29, 2018), https://www.theglobeandmail.com/technology/science/the-brain-the-final-frontierof-science/article1038205/ [https://perma.cc/72DG-TEND].
93. See Benjamin Bakondi et al., In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal
Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa, 24
MOLECULAR THERAPY 556, 556 (2016).
94. See Simona Valletta et al., ASXL1 Mutation Correction by CRISPR/Cas9 Restores
Gene Function in Leukemia Cells and Increases Survival in Mouse Xenografts, 6
ONCOTARGET 44,061, 44,062 (2015).
95. See Luhan Yang et al., Genome-Wide Inactivation of Porcine Endogenous
Retroviruses (PERVs), 350 SCIENCE 1101, 1101 (2015).
96. See Zhuchi Tu et al., Promoting Cas9 Degradation Reduces Mosaic Mutations in
Non-Human Primate Embryos, 7 SCI. REP., no. 42081, Feb. 3, 2017, at 1, 1.
97. See generally Zhao Zhang et al., CRISPR/Cas9 Genome-Editing System in Human
Stem Cells: Current Status and Future Prospects, 9 MOLECULAR THERAPY: NUCLEIC
ACIDS 230, 230 (2017) (highlighting “the basic biology and application of the
CRISPR/Cas9 system in current human stem cell research”).
98. Rodolphe Barrangou & Jennifer A. Doudna, Applications of CRISPR
Technologies in Research and Beyond, 34 NATURE BIOTECHNOLOGY 933, 937 (2016).

97 N.C. L. REV. 1359 (2019)

2019]

CRISPR IN PSYCHIATRY

1375

in cholesterol metabolism in mice.99 Further, CRISPR has also
successfully corrected genetic mutations and achieved functional
restoration of simple genetic conditions in animal models.100
In humans, a recently proposed clinical trial is looking to test the
efficacy of a CRISPR system in cancer patients.101 The researchers
will edit the immune cells of the participants.102 Scientists in China
have successfully edited genes in human embryos, replacing a
thalassemia-causing gene with its corrected form and achieving
desired results.103 U.S.-based companies have launched clinical trials
for the application of CRISPR technologies to treat the ββthalassemia blood disorder.104 Together, these applications suggest
that CRISPR might be used successfully to correct human diseases
arising from single-gene mutations, where the target is clear and the
causal underpinnings of the disease are well understood.
Particularly in the context of psychiatry and neuropsychiatric
diseases, CRISPR systems have been used to study the roles of
different proteins in directing neurodevelopment so as to better
understand the function of pathways that regulate genes and their
expression.105 Studies using CRISPR on genes implicated in Autism
Spectrum Disorder (“ASD”) have successfully induced changes in the
size and morphology of mouse neurons.106 And a study using CRISPR
99. Id.
100. See generally Nataša Savić & Gerald Schwank, Advances in Therapeutic
CRISPR/Cas-9 Genome Editing, 168 TRANSLATIONAL RES. 15 (2016) (collecting
examples of successful CRISPR applications in restoring function).
101. See Françoise Baylis & Marcus McLeod, First-in-Human Phase 1 CRISPR Gene
Editing Cancer Trials: Are We Ready?, 17 CURRENT GENE THERAPY 309, 309 (2017).
102. See id. at 310.
103. See Ewen Callaway, Embryo-Editing Research Gathers Momentum, 532 NATURE
289, 290 (2016) (discussing Puping Liang et al., CRISPR/Cas9-Mediated Gene Editing in
Human Tripronuclear Zygotes, 6 PROTEIN & CELL 363, 363 (2015)). Thalassemia is “an
inherited blood disorder characterized by the presence of less hemoglobin and fewer red
blood cells in your body than normal.” Thalassemia, MAYO CLINIC (Nov. 2, 2016),
https://www.mayoclinic.org/diseases-conditions/thalassemia/symptoms-causes/syc-20354995
[https://perma.cc/39ZX-X7ZK].
104. A Safety and Efficacy Study Evaluating CTX001 in Subjects with TransfusionDependent ββ-Thalassemia, CLINICALTRIALS.GOV, https://clinicaltrials.gov/ct2/show/
NCT03655678 [https://perma.cc/S9DJ-9GJX] (last updated Feb. 4, 2019).
105. See, e.g., Elizabeth A. Alcamo et al., Satb2 Regulates Callosal Projection Neuron
Identity in the Developing Cerebral Cortex, 57 NEURON 364, 364 (2008).
106. See, e.g., Eric Deneault et al., Complete Disruption of Autism-Susceptibility Genes
by Gene Editing Predominantly Reduces Functional Connectivity of Isogenic Human
Neurons, 11 STEM CELL REP. 1211, 1211 (2018) (“[P]resent[ing] a CRISPR gene editing
strategy to insert a protein tag and premature termination sites creating an induced
pluripotent stem cell (iPSC) knockout resource for functional studies of ten ASD-relevant
genes . . . .”); Michael R. Williams et al., A Retroviral CRISPR-Cas9 System for Cellular
Autism-Associated Phenotype Discovery in Developing Neurons, 6 SCI. REP., no. 25611,
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to knock out genetic variants repeatedly associated with
schizophrenia has helped scientists understand the impact of diseaserelevant mutations.107 Fragile X syndrome—thought to be the most
common form of inherited intellectual disability—is caused by a
known repeat in a specific gene.108 This repeat causes certain changes
to the genome.109 Using CRISPR, scientists have deleted the
nucleotide repeat known to cause Fragile X.110 The deletion reversed
some of the known harmful downstream consequences of the repeat
sequence.111
B.

CRISPR in Psychiatry: More Immediate Practical Applications

The state of the science reveals areas where CRISPR might find
more immediate practical application. As noted above, preclinical
findings of studies involving CRISPR systems suggest that the
technology might be successfully used to correct human diseases
arising from single-gene mutations, known as monogenic diseases.112
There are certain conditions with psychiatric manifestations that are
known to have monogenic causes and genetically defined symptoms.
The Diagnostic and Statistical Manual of Mental Disorders
(“DSM-5”)—the definitive manual used by psychiatrists and other
mental health experts for the diagnosis and treatment of psychiatric
disorders—devotes an entire section to neurocognitive disorders
(“NCDs”).113 Most NCDs have an adult onset.114 For many, there is a

May 10, 2016, at 1, 1 (concluding that the implementation of a CRISPR system is an
efficient system for an Autism-associated phenotype discovery in wild-type animals).
107. See Matthew D. Rannals et al., Psychiatric Risk Gene Transcription Factor 4
Regulates Intrinsic Excitability of Prefrontal Neurons via Repression of SCN10a and
KCNQ1, 90 NEURON 43, 43, 45 (2016).
108. X. Shawn Liu et al., Rescue of Fragile X Syndrome Neurons by DNA Methylation
Editing of the FMR1 Gene, 172 CELL 979, 979 (2018).
109. See id. One of the changes that occurs is DNA methylation. Methylation is the
process by which genes are turned “on” and “off.” See Cath Ennis, Epigenetics 101: A
Beginner’s Guide to Explaining Everything, GUARDIAN (Apr. 25, 2014),
https://www.theguardian.com/science/occams-corner/2014/apr/25/epigenetics-beginners-guideto-everything [https://perma.cc/RF4F-ZVGG]. When genes are on, they produce proteins.
Id.
110. See Chul-Yong Park et al., Reversion of FMR1 Methylation and Silencing by
Editing the Triplet Repeats in Fragile X iPSC-Derived Neurons, 13 CELL REP. 234, 234
(2016).
111. See id.
112. See supra notes 93–104 and accompanying text.
113. See AM. PSYCHIATRIC ASS’N, DIAGNOSTIC AND STATISTICAL MANUAL OF
MENTAL DISORDERS 591–644 (5th ed. 2013) [hereinafter DSM-5]. “The NCDs are unique
among DSM-5 categories in that these are syndromes for which the underlying pathology,
and frequently the etiology as well, can potentially be determined. The various underlying
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variation of the disorder that is inherited and for which a causative
genetic mutation has been identified.115
One such example is noted above. Fragile X presents in humans
when a single gene, known as the FMR1 gene, shuts down. When a
gene shuts down, it stops producing proteins.116 In one study, scientists
successfully applied CRISPR systems to remove the tags on the
FMR1 gene that are responsible for keeping the gene shut off.117 As a
result, the genes began producing proteins normally again, and once
the edited cells were transferred into mice, the cells continued to
produce proteins normally for a subsequent three months.118 These
results were astounding: the test achieved almost full restoration of
normal protein expression levels of the FMR1 gene.119 This means
that scientists may, in the not-so-distant future, be able to engineer a
lasting solution for Fragile X syndrome.
Similar to Fragile X, Huntington’s disease is also caused by a
single, identifiable genetic mutation.120 In cells from both animal
models and humans, CRISPR was able to deactivate Huntington’s
defective gene with remarkable efficiency.121 Clinical testing on
Huntington’s could be expected to start as early as five years from
now.122

disease entities have all been the subject of extensive research, clinical experience, and
expert consensus on diagnostic criteria.” Id. at 591.
114. Major Neurocognitive Disorder in Adults, MINDYRA, http://www.mindyra.com/
solutions/adults/majorneurocognitivedisorder [https://perma.cc/LXH5-GVCG].
115. Some of the disorders that fall within this category are as follows: NCD due to
Alzheimer’s disease, NCD due to Parkinson’s disease, NCD with Lewy Bodies,
Frontotemporal NCD, and NCD due to Huntington’s disease. DSM-5, supra note 113, at
591. For Huntington’s disease in particular, the diagnosis is made by genetic confirmation
of the causative genetic mutation. Huntington Disease, NIH: NAT’L CTR. FOR
ADVANCING TRANSLATIONAL SCI. (July 8, 2015), https://rarediseases.info.nih.gov/
diseases/6677/huntington-disease/cases/18858 [https://perma.cc/E9RF-GLLF].
116. See
Fragile
X
Syndrome,
NIH:
GENETICS HOME REFERENCE,
https://ghr.nlm.nih.gov/condition/fragile-x-syndrome#genes [https://perma.cc/5L8R-APG5] (last
updated Apr. 30, 2019).
117. See Liu et al., supra note 108, at 979.
118. Id. at 984–85.
119. See id. at 979.
120. Alex Mas Monteys et al., CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In
Vitro and In Vivo, 25 MOLECULAR THERAPY 12, 12 (2017).
121. See id. at 19–20. Increasing scientific evidence supports eliminating the distinction
between psychiatric and neurological disorders. See P. D. White, H. Rickards & A. Z. J.
Zeman, Time to End the Distinction Between Mental and Neurological Illnesses, 344 BRIT.
MED. J., no. e3454, May 24, 2012, at 1,1.
122. Michael Eisenstein, CRISPR Takes on Huntington’s Disease, NATURE (May 30,
2018), https://www.nature.com/articles/d41586-018-05177-y#ref-CR1 [https://perma.cc/4T47YVVW].
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CRISPR might also be more immediately applied to
mitochondrial disorders with psychiatric phenotypes, such as
Niemann-Pick disease. Niemann-Pick is a rare and life-threatening
condition—frequently diagnosed in children during their elementary
school years—in which cholesterol and other lipids are not properly
metabolized within the cell.123 The disease is sometimes referred to as
“childhood Alzheimer’s”124 and has a known genetic cause.125 There
are currently no viable treatments or cures for Niemann-Pick,126 but
the disorder has been identified as one that might be among the first
treated with CRISPR technologies.127
Wilson’s disease is another particularly interesting target. This
genetic disorder often presents with neuropsychiatric symptoms, but
it primarily involves the liver.128 Given that psychiatric symptoms can
be these patients’ chief complaint, a true diagnosis often eludes
clinicians for some time.129 It’s the mutation of a single gene, ATP7B,
that leads to Wilson’s disease.130 And the possibility of delivering gene
therapy to the liver is much more tractable at this time than
interventions targeting the brain directly.131

123. Niemann Pick Disease Type C, NAT’L ORG. FOR RARE DISORDERS,
https://rarediseases.org/rare-diseases/niemann-pick-disease-type-c/ [http://perma.cc/B8W7CW36].
124. Univ. of Pa., Effective Treatment for Niemann Pick Type C Identified,
SCIENCEDAILY (Feb. 25, 2015), https://www.sciencedaily.com/releases/2015/02/150225151752.
htm [http://perma.cc/T37F-U4MA].
125. Mary Gearing, Treating Muscular Dystrophy with CRISPR Gene Editing,
ADDGENE BLOG (Jan. 26, 2016, 10:30 AM), https://blog.addgene.org/treating-musculardystrophy-with-crispr-gene-editing [http://perma.cc/688P-NB5U].
126. See Erica Peacock, Gene Therapy: Bringing Hope to the Rare Disease Community,
RARE DISEASE REV. (Mar. 12, 2018), https://www.rarediseasereview.org/publications/2018/
3/12/gene-therapy-bringing-hope-to-the-rare-disease-community
[http://perma.cc/7QDMSZNK].
127. See Gearing, supra note 125.
128. Wilson Disease, NIH: NAT’L INST. DIABETES & DIGESTIVE & KIDNEY DISEASES,
https://www.niddk.nih.gov/health-information/liver-disease/wilson-disease [http://perma.cc/
48QS-FZ3Z].
129. GEORGE J. BREWER, WILSON’S DISEASE: A CLINICIAN’S GUIDE TO
RECOGNITION, DIAGNOSIS, AND MANAGEMENT 4 (2001).
130. Id. at 139.
131. As noted above, it is important to keep in mind that, although a single gene may
be involved in the etiology of these conditions, there may be multiple causative mutations
within that single gene.
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Likelihood of CRISPR Applications to Polygenic Psychiatric
Disorders

With technology as it currently stands, targeting psychiatric
disorders caused by multiple genes—polygenic conditions132—is a
distant reality. To be sure, recent preclinical studies have managed to
enhance CRISPR’s target specificity and use certain CRISPR systems
containing multiple guide RNAs to target many genes at once—a task
known as multiplexing.133 But because of the complicated and largely
unknown genetic architecture of polygenic psychiatric disorders,
along with the effects of complex epigenetic processes for which we
still can’t account, CRISPR clinical applications in this area aren’t
likely an imminent reality. Even if CRISPR were shown to be
efficacious in a clinical setting, the editing targets for most psychiatric
disorders—certainly all polygenic psychiatric disorders—are not yet
clear.
One reason for this complexity is the lack of understanding about
the role of noncoding, gene-regulatory regions in neuropsychiatric
disease. The coding region of a gene contains the instructions for the
production of proteins. Coding regions make up about one percent of
all DNA.134 Noncoding regions make up the other ninety-nine percent
and, until very recently, were referred to as “junk DNA.” Noncoding
regions were thought to have no purpose at all.135 Consequently,
much of the research in genetics has been focused on DNA’s coding
regions.136 As it turns out, however, this focus may have been
misguided, as noncoding regions play a more important role in
polygenic disorders than was previously believed. For instance, one
article identified 108 loci associated with schizophrenia, and a great
many happened to occur in noncoding regions.137 Accordingly, though
132. What Are Complex or Multifactorial Disorders?, NIH: GENETICS HOME
REFERENCE, https://ghr.nlm.nih.gov/primer/mutationsanddisorders/complexdisorders
[https://perma.cc/5SBD-BDSA] (last updated Apr. 30, 2019).
133. Mary Gearing, CRISPR 101: Multiplex Expression of gRNAs, ADDGENE BLOG
(Jan. 28, 2016, 10:50 AM), https://blog.addgene.org/crispr-101-multiplex-expression-of-grnas
[http://perma.cc/5CWM-MD5N].
134. Jonathan Henninger, The 99 Percent . . . of the Human Genome, HARV. U.: SCI.
NEWS (Oct. 1, 2012), http://sitn.hms.harvard.edu/flash/2012/issue127a/ [http://perma.cc/
7VQ3-RXR7].
135. Stephen S. Hall, Hidden Treasures in Junk DNA, SCI. AM. (Oct. 1, 2012),
https://www.scientificamerican.com/article/hidden-treasures-in-junk-dna/ [http://perma.cc/
3WUN-8E6S].
136. Id.
137. Schizophrenia Working Grp. of the Psychiatric Genomics Consortium, Biological
Insights from 108 Schizophrenia-Associated Loci, 511 NATURE 421, 421–22 (2014) (“Of
the 108 loci, 75% include protein-coding genes . . . .”).
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noncoding regions are now garnering more attention, further
investigation is still needed to fully understand their role in
neuropsychiatric diseases.
Among polygenic psychiatric disorders, the genetics of
schizophrenia are best understood. This is, in part, due to the fact that
the heritability of schizophrenia has been estimated to be as high as
eighty-seven percent.138 After decades of research, it has been
determined that genes play a very important role in the development
of schizophrenia. Scientists have successfully located multiple
alterations in the genomic DNA of neurons and discovered that they
are, in fact, likely responsible for causing the disorder.139 Yet obstacles
such as CRISPR’s inability to cross the blood-brain barrier, lack of
definite targets, genetic overlap between schizophrenia and other
psychiatric conditions, and lack of knowledge about the efficacy and
long-term safety of CRISPR systems mean there is a long way to go
before CRISPR technologies can be translated into a clinical cure for
schizophrenia.140
Another obstacle to applying CRISPR for the treatment of
psychiatric disorders concerns neurodevelopmental disorders. Take,
for example, intellectual developmental disorder (“IDD”) and ASD.
Sequencing efforts of IDD cases have been successful. Studies have
now identified a genetic cause for up to forty percent of severe IDD
cases.141 But for many of the genetically defined IDD cases, most of
the deleterious effects of the identified pathogenic genomic variants
may have already taken place by the time of diagnosis.142 This is the
case even though the diagnosis can take place as early as in utero.143 It
is not apparent that changing a pathogenic variant after birth would
correct the associated behaviors and phenotype.
Nonetheless, it is possible that repair by CRISPR may improve
some aspects of psychiatric symptomatology. After all, current
138. See Alastair G. Cardno et al., Heritability Estimates for Psychotic Disorders: The
Maudsley Twin Psychosis Series, 56 ARCHIVES GEN. PSYCHIATRY 162, 162 (1999). This
means the closer the familial relationship, the higher the risk for developing schizophrenia.
139. Stephan Ripke et al., Genome-Wide Association Analysis Identifies 13 New Risk
Loci for Schizophrenia, 45 NATURE GENETICS 1150, 1150 (2013).
140. Chuanjun Zhuo et al., Genomic Editing of Non-Coding RNA Genes with
CRISPR/Cas9 Ushers in a Potential Novel Approach to Study and Treat Schizophrenia, 10
FRONTIERS MOLECULAR NEUROSCIENCE, no. 28, Feb. 3, 2017, at 1, 6–7.
141. Simone M. Karam et al., Genetic Causes of Intellectual Disability in a Birth
Cohort: A Population-Based Study, 167A AM. J. MED. GENETICS 1204, 1211 (2015).
142. Id. at 1207.
143. See Regie Lyn P. Santos-Cortez et al., Novel Candidate Genes and Variants
Underlying Autosomal Recessive Neurodevelopmental Disorders with Intellectual
Disability, 137 HUM. GENETICS 735, 744 (2018).
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psychopharmacologic treatments available today, which target
behaviors, do not directly address underlying structural
abnormalities.144
A final important consideration is the fact that many of the
identified causative variants are exceedingly rare. That is, though a
particular gene may have clear associations with IDD, there are often
numerous variants within that gene that led to each particular
individual’s case of IDD.145 Targeting and identifying each and every
one of those possible pathogenic variants within the single gene
presents another daunting challenge.
Certainly, CRISPR techniques hold much promise as important
tools in helping us understand the biology underlying
neuropsychiatric disorders. CRISPR is illuminating pathways beyond
the reach of older technologies.146 Its translation into the clinical
setting, however, would necessarily depend upon its ability to reveal
the biological mechanisms responsible for psychiatric conditions.
For the time being, therefore, the brain remains a daunting
target. Given its cellular and structural complexity, relative
inaccessibility, irreplaceable function, and minimal regenerative
capacity, neuropsychiatric conditions will not likely serve as
CRISPR’s initial testing grounds. But CRISPR technology is
developing quickly, and clinical applications in the future—for certain
disorders—are no longer improbable hypotheticals.147 Before these
become a reality, scientists and clinicians need a better understanding
of the technology and its unintended effects.148 Likewise, many have
called for discourse on the ethical issues implicated by CRISPR
applications.149

144. Laura Weiss Roberts & Shaili Jain, Ethical Issues in Psychopharmacology,
PSYCHIATRIC TIMES (May 7, 2011), http://www.psychiatrictimes.com/geriatric-psychiatry/
ethical-issues-psychopharmacology [http://perma.cc/S9MD-7CTT].
145. See generally Jay W. Ellison, Jill A. Rosenfeld & Lisa G. Shaffer, Genetic Basis of
Intellectual Disability, 64 ANN. REV. MED. 441 (2013) (discussing how the proliferation of
microarray analysis has led scientists to the conclusion that there is “extensive genetic
heterogeneity” for intellectual disability).
146. For example, scientists are developing reliable animal models and investigating
the role of long noncoding RNA functions and higher-order chromatin structures.
Prashanth Rajarajan et al., Spatial Genome Organization and Cognition, 17 NATURE
REVIEWS: NEUROSCIENCE 681, 688 (2016).
147. See id. at 685.
148. See, e.g., Zhuo et al., supra note 140, at 6–7.
149. Id.
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III. LEGAL AND ETHICAL CHALLENGES OF CRISPR IN THE
CONTEXT OF PSYCHIATRIC ILLNESS
The use of CRISPR technologies in psychiatric populations must
conscientiously regard the dubious past of American law on the
intersection of psychiatric disorders and genetics. The legal and
ethical issues that arise as CRISPR technologies become available
have, to some extent, all been seen before. After all, the goal of gene
therapy could be characterized as removing genetic defects from the
population. And what is the genetic cleansing of a human population
if not the issue addressed by the incendiary Supreme Court decision
in Buck v. Bell?150 Careful thought will be particularly important
within the delicate context of psychiatry given this subgroup’s.151
A. Vulnerability of Patients Likely to Enlist in CRISPR Research in
Psychiatry
Attempts to define vulnerability within the medical community
have been criticized by some for being wildly inconsistent and for
producing definitions that are entirely too broad.152 As we have noted
above, the medical community typically includes those diagnosed with
mental illness within the vulnerable population label.153 For research
purposes, however, patients diagnosed with psychiatric disorders
historically have not been labeled as vulnerable, and those enrolled in
clinical trials for psychiatric disorders are therefore not always

150. 274 U.S. 200 (1927). In this case, the United States Supreme Court reviewed the
constitutionality of Virginia’s Sterilization Act, under the authority of which the State
proposed to have Carrie Buck sterilized. Id. at 205–06. Officials of the Virginia Colony
asserted that Carrie and her mother shared the hereditary traits of feeblemindedness and
sexual promiscuity. Id. The Court voted 8-1 to allow Buck’s sterilization and, by extension,
the sterilization of any other American in similar circumstances. See id. at 207. Justice
Holmes, writing for the majority, concluded with the unfortunate remark: “Three
generations of imbeciles are enough.” Id.
151. In the domain of health care, vulnerable populations include those with chronic
mental conditions such as schizophrenia, bipolar disorder, and major depression. As we
will address later, this designation does not extend into the domain of clinical research. See
Samia A. Hurst, Vulnerability in Research and Health Care; Describing the Elephant in the
Room?, 22 BIOETHICS 191, 192 (2008). The vulnerable-population label denotes a
reference to a disadvantaged subsegment of people. Id. at 191–92. The term for our
purposes implies that these subgroups require utmost care, given that their freedom and
capability to protect themselves from intended or inherent risks is abbreviated, be it from
an impairment of freewill or an inability to make informed choices. See id.
152. See Philip T. Yanos, Barbara S. Stanley & Carolyn S. Greene, Research Risk for
Persons with Psychiatric Disorders: A Decisional Framework to Meet the Ethical
Challenge, 60 PSYCHIATRIC SERVICES 374, 375 (2009).
153. See supra note 151.
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afforded additional safeguards.154 In the sections that follow, we’ll
consider whether subjects enrolled in CRISPR clinical trials should be
labeled as a vulnerable population for research purposes. In so doing,
we describe the likely characteristics shared by these patients and
turn to both examples of capacity155 and power-based vulnerabilities156
affecting these subjects.
1. The Population Most Likely to Undergo CRISPR Clinical Trials Is
Treatment Resistant
Despite the vast amounts of resources invested into the
exploration of their genetic architecture, there are still no biomarkers
that allow for conclusive diagnoses of major psychiatric disorders.157
In a sense, much of clinical practice in psychiatry still relies on selfreports, observations, and trial-and-error treatment selection.158 That
is, biologically heterogeneous conditions in psychiatry are often
treated generally, since treatments that are most likely to help a
particular individual cannot be identified.159
To be sure—and as Section II.A illustrates—the explosion of
research in genetics, particularly in the field of psychiatry, has
produced some fruitful information.160 Psychiatric disorders’ high
rates of heritability have become more apparent than ever before.161
Simultaneously, these studies reveal that, for most disorders, there is
a complex genetic architecture that provides multiple potential
targets for CRISPR interventions. Though most of the genes
identified are only responsible in very small part for the overall risk of
developing a disorder,162 as noted above, there are variants that seem
154. See, e.g., 45 C.F.R. § 46.107 (2018) (not including those diagnosed with psychiatric
disorders in its list of vulnerable populations).
155. Capacity-based vulnerability is the vulnerability that arises as a consequence of
subjects having an impaired capacity to provide fully informed consent. See Yanos et al.,
supra note 152, at 375.
156. Power-based vulnerability is vulnerability due to a population being generally
more susceptible to social influence and the commands of authority figures. Id.
157. Daniel Moreno-De-Luca, Michael E. Ross & David A. Ross, Leveraging the
Power of Genetics to Bring Precision Medicine to Psychiatry: Too Little of a Good Thing?,
83 BIOLOGICAL PSYCHIATRY e45, e45 (2018).
158. See JAMES H. LAKE, TEXTBOOK OF INTEGRATIVE MENTAL HEALTH CARE 18
(2007).
159. See Moreno-De-Luca et al., supra note 157, at e45.
160. See id.
161. See id.; see also Gandal et al., supra note 3, at 1397. Most notably, the genetic
contribution to the condition of schizophrenia has been placed at seventy-nine percent.
Rikke Hilker et al., Heritability of Schizophrenia and Schizophrenia Spectrum Based on
the Nationwide Danish Twin Register, 83 BIOLOGICAL PSYCHIATRY 492, 495 (2018).
162. See Moreno-De-Luca et al., supra note 157, at e45.
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more promising. That said, for a majority of conditions, there is still a
great deal left to learn.
Even if a psychiatric disorder presented with clear symptoms and
had a clear genetic target the prospect of CRISPR intervention poses
dilemmas. First, there are likely biological consequences to living with
a pathogenic variant for years,163 and it’s likely that these
consequences cannot be immediately accounted for by simply
replacing the affected gene sequence with a new one. Second, we are
only beginning to understand the genetic architecture of psychiatric
disorders, as well as the epigenetic components of psychiatric
symptomatology.164 Targeting genes that are believed to be
responsible for disorders may not have the intended therapeutic
effect because the intervention does not address the epigenetics
involved in the etiology of the condition.
Against this background, it becomes clear that treatments
applying CRISPR systems should be thought of as highly
experimental.165 And because it intends to change one of the most
fundamental aspects of our biology, CRISPR should be understood as
highly invasive. Clinical trials looking to apply invasive and
experimental technologies to psychiatric populations provide ample
precedent for a description of the groups usually recruited for
enrollment. For example, Electroconvulsive Therapy (“ECT”) trials
are usually conducted on patient populations that are considered
treatment resistant: patients who have tried numerous interventions
to no avail.166 ECT is considered highly invasive for a number of
163. A pathogenic variant can be thought of as a “faulty gene.”
164. See Rachel Yehuda et al., Holocaust Exposure Induced Intergenerational Effects
on FKBP5 Methylation, 80 BIOLOGICAL PSYCHIATRY 372, 379 (2016).
165. See David Crow, CRISPR Gene Editing Ready for Testing in Humans, FIN. TIMES
(Mar. 5, 2018), https://www.ft.com/content/d6a773a0-cece-11e7-947e-f1ea5435bcc7
[http://perma.cc/2VUT-834X] (“The field is in its infancy and progress in any new area of
science is never smooth.”).
166. See Nancy Kerner & Joan Prudic, Current Electroconvulsive Therapy Practice and
Research in the Geriatric Population, 4 NEUROPSYCHIATRY 33, 34 (2014) (“[ECT] is
utilized worldwide for various severe and treatment-resistant psychiatric disorders.”); Eric
L. Ross, Kara Zivin & Daniel F. Maixner, Cost-Effectiveness of Electroconvulsive Therapy
vs Pharmacotherapy/Psychotherapy for Treatment-Resistant Depression in the United
States, 75 JAMA PSYCHIATRY 713, 714 (2018) (“Although ECT can be a first-line
treatment for depression with life-threatening psychotic or suicidal features, it is most
often used in the United States for depression that has failed to respond to
pharmacotherapy and/or psychotherapy.”); What Is Electroconvulsive Therapy (ECT)?,
A M.
PSYCHIATRIC
ASS’N,
https://www.psychiatry.org/patients-families/ect
[http://perma.cc/FF7H-6S85] (“Electroconvulsive therapy (ECT) is a medical treatment
most commonly used in patients with severe major depression or bipolar disorder that has
not responded to other treatments.”). The definition of “treatment resistance” in
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reasons, primarily the need for general anesthesia during the
therapy’s administration.167 Similarly, experimental trials in psychiatry
involving the use of ketamine, scopolamine, and other psychedelics
target treatment-resistant patients.168 The same is true of trials
involving invasive deep brain stimulation procedures.169 Invasive and
innovative interventions are usually reserved for those patients who
either have not responded to numerous treatments over a long period
of time and have been continuously affected by the symptoms they
deem undesirable170 or those who have been unable to tolerate the
side effects of traditional psychotropic medications.
Arguably, intervention with gene-editing technologies is more
invasive than intervention with ECT, ketamine, and the other highly
invasive treatments discussed above. Unlike currently available
interventions, treatment with CRISPR for psychiatric disorders would
likely entail direct exposure of biologics to the brain, lead to
permanent change in the patient’s genetic blueprint, and require

psychiatry varies and is usually defined in the context of the disorder diagnosed. For
example, treatment-resistant depression “typically refers to the occurrence of an
inadequate response following adequate antidepressant therapy among patients suffering
from unipolar depressive disorders.” Maurizio Fava, Diagnosis and Definition of
Treatment-Resistant Depression, 53 BIOLOGICAL PSYCHIATRY 649, 649 (2003). In the
context of schizophrenia, treatment resistance—also known as treatment refractoriness—
has been “defined as continuing psychotic symptoms with substantial functional disability
and/or behavioral deviances that persist in well-diagnosed persons with schizophrenia
despite reasonable and customary pharmacological and psychosocial treatment that has
been provided continuously for an adequate time period.” Hans D. Brenner et al.,
Defining Treatment Refractoriness in Schizophrenia, 16 SCHIZOPHRENIA BULL. 551, 552–
53 (1990); see also Norman Sussman, Introduction: Treatment Resistance in Psychiatry,
PSYCHIATRIC TIMES (Nov. 27, 2017), https://www.psychiatrictimes.com/special-reports/
introduction-treatment-resistance-psychiatry [https://perma.cc/2DZB-2GHZ].
167. See What Is Electroconvulsive Therapy (ECT)?, supra note 166.
168. See, e.g., James W. Murrough et al., Antidepressant Efficacy of Ketamine in
Treatment-Resistant Major Depression: A Two-Site Randomized Controlled Trial, 170 AM.
J. PSYCHIATRY 1134, 1135 (2013); Chun Yang & Kenji Hashimoto, Letter to the Editor,
Combination of Nitrous Oxide with Isoflurane or Scopolamine for Treatment-Resistant
Major Depression, 13 CLINICAL PSYCHOPHARMACOLOGY & NEUROSCIENCE 118, 118
(2015); see also Carlos Zarate et al., New Paradigms for Treatment-Resistant Depression,
1292 ANNALS N.Y. ACAD. SCI. 21, 25 (2013).
169. See Paul E. Holtzheimer & Helen S. Mayberg, Deep Brain Stimulation for
Psychiatric Disorders, 34 ANN. REV. NEUROSCIENCE 289, 290 (2011).
170. Although a precise definition of treatment resistance is hard to come by and often
varies depending on the particular psychiatric disorder at issue, some have characterized
treatment resistance as “patients who experience persistent psychiatric symptoms with
impaired functioning despite one or more adequate treatment trials.” L. Fredrik Jarskog,
Book Review, 171 AM. J. PSYCHIATRY 374, 374 (2014) (reviewing CHARLES B.
NEMEROFF, MANAGEMENT OF TREATMENT-RESISTANT MAJOR PSYCHIATRIC
DISORDERS (2012)); see also supra note 166.
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genetic sequencing prior to CRISPR’s application.171 Therefore, it is
reasonable to assume that, if and when the technology is developed,
the same population of treatment-resistant patients would make for
the best candidates for CRISPR clinical trials in psychiatry. To be
sure, if gene-editing technology trials of the past are any indication,
those who enroll in these research studies will be treatment resistant
and may be willing to consider riskier interventions to address their
symptoms.172
2. Risk-Benefit Analysis for Testing CRISPR in Treatment-Resistant
Populations
The target of treatment for patients with psychiatric disorders is
“to restore a state of psychological wellness and high functioning.”173
In deciding how to reach this goal, physicians must conduct a riskbenefit analysis for prescribing psychotropic medications or
alternative therapies. As this analysis relates to any patient diagnosed
with a psychiatric disorder, the balancing is particularly complex.174
Lackluster therapeutic and diagnostic precision, psychosocial factors,
common comorbidities, and the high importance given to the
subjective experiences of patients complicate the prescribing
physicians’ decisionmaking processes.175 For a favorable risk-benefit
ratio to exist, biological, psychological, and social factors must align.176
The already delicate balance changes when a patient diagnosed with a
psychiatric disorder experiences treatment resistance.
Treatment-resistant patients typically feel debilitated for a long
period of time,177 experience feelings of hopelessness and

171. The privacy implications of gathering genetic-sequencing information from
patients prior to treatment are discussed infra Section III.A.3.
172. See Friedmann, supra note 57, at 2163–65. In the alternative, as noted in Section
II.B, trials will target monogenic diseases for which there is no cure. Just like treatmentresistant patients, the patients affected by the monogenic disorders that have no viable
treatment alternatives are most likely to be targeted by CRISPR in the near future. Both
groups face parallel ethical dilemmas as a result. This discussion, therefore, will proceed
by considering the implications of clinical research in a treatment-resistant population.
173. Maurizio Fava & Katharine G. Davidson, Definition and Epidemiology of
Treatment-Resistant Depression, 19 PSYCHIATRIC CLINICS N. AM. 179, 179 (1996).
174. Swapnil Gupta & John Daniel Cahill, A Prescription for “Deprescribing” in
Psychiatry, 67 PSYCHIATRIC SERVICES 904, 904 (2016).
175. Id.
176. Id.
177. See Jarskog, supra note 170, at 375 (“Most [psychiatric] disorders do not have
formally defined treatment-resistant subtypes, but the prevalence of persistent and
debilitating symptoms is a ubiquitous problem.”).
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helplessness,178 and may be at risk of suicide.179 Therefore, treatmentresistant patients—along with their treating physicians—are generally
more willing to take risks to find a solution.180 Accordingly,
institutional review boards and other regulatory bodies are more
likely to allow invasive interventions if the population being treated is
treatment-resistant and/or has few or no alternative options. After all,
the risk of not acting might outweigh any risks that an invasive
intervention like CRISPR might pose.181 Ultimately, however,
clinicians and researchers should understand the characteristics and
symptoms of treatment-resistant patients as having the effect of
altering not only the risk-benefit analysis for available treatment
options but also the power differential between patients, clinicians,
and researchers. As a particularly affected subgroup of a population
already stigmatized and underserved,182 treatment-resistant
individuals should be considered at high risk for power-based
vulnerability and coercion.
3. Treatment-Resistant Patients with Psychiatric Conditions Are
Highly Stigmatized
To some extent, the severity or presentation of treatmentresistant conditions is intertwined183 with the stigma faced by all
individuals diagnosed with psychiatric disorders.184 Issues of powerbased vulnerability also arise if one considers the consequences of
stigma attached to mental health issues. A clinician or researcher who
178. See, e.g., Murrough et al., supra note 168, at 1134 (“The primary outcome was
change in depression severity . . . as assessed by the Montgomery-Åsberg Depression
Rating Scale.”); see also Stuart A. Montgomery & Marie Åsberg, A New Depression Scale
Designed to be Sensitive to Change, 134 BRIT. J. PSYCHIATRY 382, 388 (1979) (measuring,
among other things, whether subjects experienced “feeling[s] of being beyond help and
without hope”).
179. See Isidoor O. Bergfeld et al., Treatment-Resistant Depression and Suicidality, 235
J. AFFECTIVE DISORDERS 362, 362 (2018).
180. See, e.g., Celia B. Fisher et al., Ethical Issues in Including Suicidal Individuals in
Clinical Research, IRB: ETHICS & HUM. RES., Sept.–Oct. 2002, at 9, 9–13.
181. See Bergfeld et al., supra note 179, at 362 (discussing the high rates of suicide
attempts amongst treatment-resistant populations).
182. See Yanos et al., supra note 152, at 374.
183. Elise Stobbe, Resistance to Seeking Treatment for Mental Illness—How Others
Can Help, BRAINBLOGGER (May 27, 2006), http://brainblogger.com/2006/05/27/antistigmatization-resistance-to-seeking-treatment-for-mental-illness-how-others-can-help/
[http://perma.cc/82GT-9H48] (“More than any other reason, stigma, or fear of the
consequences of being labeled ‘mentally ill’, prevents a person—who realizes he or she
may need help—from reaching out for that help.”).
184. See Cody Brannan, Alexandra L. Foulkes & Gabriel Lázaro-Muñoz, Preventing
Discrimination Based on Psychiatric Risk Biomarkers, 180B AM. J. MED. GENETICS 159,
162 (2019).
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possesses the information regarding a patient’s mental health has the
power to misuse and mishandle the information and thereby has the
power to potentially subject her patient to the stigma associated with
the information’s improper publication. And so, to better understand
the vulnerability of the population likely to be among the first to
undergo CRISPR treatments in psychiatry, a good understanding of
the evidence of mental health stigma and its implications is
indispensable.
Generally, stigma encompasses different elements of
stereotyping, segregation, status loss, and discrimination.185 Numerous
studies have established that mental health stigma is highly
prevalent.186 Negative attitudes toward patients of psychiatry aren’t
limited to the general lay population. Rather, negative attitudes are
often widespread among clinicians themselves.187 Stigma often leads
to discriminatory actions. For example, there is evidence that patients
diagnosed with psychiatric conditions are being paid lower wages than
their undiagnosed counterparts.188 Those diagnosed with psychiatric
conditions also generally have lower chances of obtaining and
keeping employment and receive subpar insurance benefits.189
Further, those stigmatized often report being aware of the fact that
society undervalues them and actively experience routine unfair
treatment and avoidance by other people.190 It has also been
suggested that those suffering from treatment-resistant conditions
experience more severe stigma than other patients diagnosed with
psychiatric conditions.
Known stigma against those with treatment-resistant psychiatric
disorders raises related concerns about privacy,191 especially in light of
the fact that CRISPR interventions would likely require collecting
185. Id. (quoting Bruce G. Link & Jo C. Phelan, Conceptualizing Stigma, 27 ANN.
REV. SOC. 363, 367 (2001)).
186. See, e.g., Matthias C. Angermeyer & Herbert Matschinger, The Stereotype of
Schizophrenia and Its Impact on Discrimination Against People with Schizophrenia:
Results from a Representative Survey in Germany, 30 SCHIZOPHRENIA BULL. 1049, 1049
(2004); Yoko Baba et al., Stigma Toward Psychosis and Its Formulation Process: Prejudice
and Discrimination Against Early Stages of Schizophrenia, 73 COMPREHENSIVE
PSYCHIATRY 181, 181 (2017); Patrick W. Corrigan, Fred E. Markowitz & Amy C. Watson,
Structural Levels of Mental Illness Stigma and Discrimination, 30 SCHIZOPHRENIA BULL.
481, 481–89 (2004).
187. Brannan et al., supra note 184, at 4.
188. Id.
189. Id.
190. Id.
191. See Laura Plantinga et al., Disclosure, Confidentiality, and Families: Experiences
and Attitudes of Those with Genetic Versus Nongenetic Medical Conditions, 119C AM. J.
MED. GENETICS 51, 51–52 (2003).
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participants’ genetic information. Studies reveal significant public
concerns about genetic privacy.192 Interestingly, people express
greater concern about protecting the privacy of their mental health
records than the privacy of their genetic information.193 Patients
finding themselves involved in an intervention requiring both the
disclosure of genetic information and mental health history should be
considered especially vulnerable. In an effort to reduce further
exposure to potentially hazardous stigma and its consequences,
clinicians and researchers should take particular care to protect this
population from improper disclosure and misuse of medical
information, all while operating within a system that gives more
protection to medical information in general.194 Scientists should
likewise be aware of the fact that having genetic and mental health
information at their disposal changes the power balance between
themselves and the research subject.
4. Vulnerabilities Surrounding Decisionmaking Capacity
Along with power-based vulnerabilities, patients first enrolled
into CRISPR clinical trials in psychiatry may likely encounter
vulnerabilities stemming from issues of informed consent. The
decision to undergo a treatment using CRISPR is something that
must be driven by the individual’s desire to eliminate certain
symptoms and the consequences of these symptoms from the patient’s
life. That is, as opposed to targeting a specific genetic profile
generally.195 But what happens if—in the midst of complicated power
dynamics
and
unwieldy
risk
assessments—the
patient’s
decisionmaking capacity is impaired? To what extent may treatmentresistant populations be so affected by their cognitive impairments
that they become unable to give meaningful informed consent?
Available research tells us that the answer to these questions is far
from clear. Nonetheless, there are reasons for ascribing safeguards to
informed consent procedures involving treatment-resistant psychiatric
192. Id. at 52.
193. See id. at 55 tbl.III, 58. In a study involving 600 individuals—100 from each of six
disease groups—at a major medical center, individuals were asked whether specific
privacy protections should be in place for certain medical conditions. In relevant part,
68.6% responded that abortion history should be protected, 60.1% were concerned about
mental health history, 54.0% about HIV/AIDS status, 46.5% about genetic test results,
and 44.4% about drug and alcohol history. Id. at 55 tbl.III.
194. See LORI B. ANDREWS, FUTURE PERFECT: CONFRONTING DECISIONS ABOUT
GENETICS 140–42 (2001); Brannan et al., supra note 184, at 4–5.
195. Otherwise, these interventions would start treading dangerously close to the
eugenics movements of the past. See infra Section III.B.2.
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populations, especially for invasive and experimental interventions
such as those involving CRISPR systems.
While there is no bright-line rule for determining when an
individual has decisionmaking capacity to consent to treatment or
research interventions, several studies have documented the degree to
which persons with psychiatric disorders are able to do so.196 Two
notable conclusions can be drawn from this data. First, a majority of
patients
diagnosed
with
psychiatric
disorders—particularly
schizophrenia—have the decisionmaking capacity to provide
informed consent.197 Second, researchers found that it is typical for a
person diagnosed with a psychiatric disorder to have an
understanding of the research that is subpar to the understanding of
persons without psychiatric disorders.198 The recruitment source for
the study and whether the protocol calls for inpatient or outpatient
treatment impacts the proportion of participants who demonstrated
capacity to provide informed consent.199 For example, a trial with
long-term inpatients concluded that sixty-seven percent of persons
with schizophrenia performed inadequately on tests of decisional
impairment.200 But others found that only twenty percent to thirty
percent of persons with schizophrenia from predominantly outpatient
samples showed evidence of decisional impairment.201
These findings suggest that although diminished capacity is an
important consideration in regard to persons who have psychiatric
disorders, it nevertheless is not universal or even typical. And
therefore, it may be best to consider this vulnerability as likely to
fluctuate with mental state. Determining how to gauge and act on the

196. See Laura B. Dunn, Capacity to Consent to Research in Schizophrenia: The
Expanding Evidence Base, 24 BEHAV. SCI. & L. 431, 432, 435–36 (2006).
197. See id. at 436–37, 440. We refer to trials on patients diagnosed with schizophrenia
because phenotypes associated with the disorder are typically more likely to affect
decisionmaking capacity than with other common psychiatric conditions. For example,
trials have found that more than ninety percent of participants with major depression
demonstrated full consent comprehension. Paul S. Appelbaum et al., Competence of
Depressed Patients for Consent to Research, 156 AM. J. PSYCHIATRY 1380, 1382 (1999).
198. See Dunn, supra note 196, at 441.
199. Compare William T. Carpenter et al., Decisional Capacity for Informed Consent in
Schizophrenia Research, 57 ARCHIVES GEN. PSYCHIATRY 533, 533 (2000) (both inpatient
and outpatient), with Jeffery A. Kovnick et al., Competence to Consent to Research Among
Long-Stay Inpatients with Chronic Schizophrenia, 54 PSYCHIATRIC SERVICES 1247, 1247
(2003) (inpatient only), and Barton W. Palmer et al., Assessment of Capacity to Consent to
Research Among Older Persons with Schizophrenia, Alzheimer Disease, or Diabetes
Mellitus, 62 ARCHIVES GEN. PSYCHIATRY 726, 726 (2005) (outpatient only).
200. See Kovnick et al., supra note 199, at 1250.
201. See Palmer et al., supra note 199, at 729–30.
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likelihood of this vulnerability being present is an ethical issue
CRISPR researchers will have to resolve.
5. Regulatory Treatment of Patients with Psychiatric Disorders as a
Vulnerable Population
Notwithstanding both the power-based and consent-based
vulnerabilities we have identified above, there are currently no
consistent federal or state regulations instituting prudent safeguards.
Under the current guidelines from the DHHS, there are no special
procedures guiding research involving persons diagnosed with
psychiatric disorders of any severity.
Regulations governing human subject research in the United
States—when said research is either funded by or committed to the
oversight of any of fifteen federal departments—are detailed in what
is known as the Common Rule.202 The Common Rule is meant to
codify the following principles, inter alia, and put them into practice:
(1) respect for the autonomous decisionmaking of those capable of
providing it and (2) providing protection for persons with diminished
autonomy.203 As such, the Common Rule seeks to ensure voluntary
participation in research through informed consent.204 In 2011, for the
first time in a long time, DHHS set out to revise the Common Rule.205
These revisions followed a call to the research committee, prompted
by DHHS, for “information and comments about whether guidance
or additional regulations are needed” for research involving people
who have impaired decisionmaking capacity, such as people who have
psychiatric disorders.206 A final rule was adopted in June 2018 and

202. U.S. Dep’t of Health & Human Servs., Federal Policy for the Protection of Human
Subjects (‘Common Rule’), OFF. FOR HUM. RES. PROTECTIONS, https://www.hhs.gov/ohrp/
regulations-and-policy/regulations/common-rule/index.html [https://perma.cc/NP4Y-GHHQ].
203. See NAT’L COMM’N FOR THE PROT. OF HUMAN SUBJECTS OF BIOMEDICAL &
BEHAVIORAL RESEARCH, THE BELMONT REPORT: ETHICAL PRINCIPLES AND
GUIDELINES FOR THE PROTECTION OF HUMAN SUBJECTS OF RESEARCH 4–5
[hereinafter THE BELMONT REPORT], https://videocast.nih.gov/pdf/ohrp_belmont_report.
pdf [https://perma.cc/7F5X-54FG].
204. See 45 C.F.R. § 46.116(b)(8) (2018); THE BELMONT REPORT, supra note 203, at 10
(“[T]he consent process can be analyzed as containing three elements: information,
comprehension and voluntariness.”).
205. See Human Subjects Research Protections: Enhancing Protections for Research
Subjects and Reducing Burden, Delay, and Ambiguity for Investigators, 76 Fed. Reg.
44,512, 44,512 (July 26, 2011).
206. Request for Information and Comments on Research that Involves Adult
Individuals with Impaired Decision-Making Capacity, 72 Fed. Reg. 50,966, 50,966 (Sept. 5,
2007).
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took effect in January 2019.207 The final rule does not explicitly
include those diagnosed with psychiatric disorders as a vulnerable
population.208 Rather, the new Common Rule uses the phrase
“individuals with impaired decision-making capacity” to replace the
phrase “mentally disabled persons.”209 So, while DHHS’s guidebook
for institutional review boards excludes mention of those diagnosed
with psychiatric disorders from its instructions on procedures for
research involving special classes of human subjects, it is possible
these new regulations would encourage a different approach.210
Guidance from states on what to do when decisionmaking abilities
are insufficient so as to require additional safeguards is sparse and
inconsistent.211 At times these guidelines are altogether absent.212
Some institutional review boards already apply different
standards to studies involving persons with psychiatric disorders.213
And, outside of the research context, the medical community has
included patients diagnosed with psychiatric conditions under the
label of “vulnerable population.”214 Given the likely profile of
patients to be first exposed to CRISPR research in psychiatry,
safeguards for ensuring the protection of patients’ best interests
should be firmly in place as a means of mitigating this population’s
potential vulnerabilities. Again, the critiques of previous trials
involving gene-editing technologies provide important insight. Critics
of early trials explicitly called for an improvement to the way

207. Federal Policy for the Protection of Human Subjects: Six Month Delay of the
General Compliance Date of Revisions While Allowing the Use of Three BurdenReducing Provisions During the Delay Period, 83 Fed. Reg. 28,497, 28,497 (June 19, 2018);
Federal Policy for the Protection of Human Subjects: Delay of the Revisions to the
Federal Policy for the Protection of Human Subjects, 83 Fed. Reg. 2885, 2886 (Jan. 22,
2018).
208. See generally Federal Policy for the Protection of Human Subjects, 82 Fed. Reg.
7149, 7264 (Jan. 19, 2017) (codified in scattered Titles of the C.F.R.) (explaining that
vulnerable populations include “children, prisoners, individuals with impaired decisionmaking capacity, or economically or educationally disadvantaged persons”).
209. See id. at 7204.
210. See generally U.S. Dept. of Health & Human Servs., Chapter VI: Special Classes of
Subjects, INSTITUTIONAL REV. BOARD GUIDEBOOK (1993), http://wayback.archive-it.org/
org-745/20150930182815/http://www.hhs.gov/ohrp/archive/irb/irb_chapter6.htm [https://perma.cc/
LEM2-T7H6] (providing IRBs with additional guidance for managing research involving special
classes of vulnerable subjects).
211. See Erin S. DeMartino et al., Who Decides When a Patient Can’t? Statutes on
Alternate Decision Makers, 376 NEW ENG. J. MED. 1478, 1481 (2017).
212. Id. at 1480 fig.1.
213. See Yanos et al., supra note 152, at 374.
214. See LU ANN ADAY, AT RISK IN AMERICA: THE HEALTH AND HEALTH CARE
NEEDS OF VULNERABLE POPULATIONS IN THE UNITED STATES 15 (1993).
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clinicians obtain informed consent.215 The informed consent process,
critics claimed, needs to be made as thorough as possible to safeguard
the population of patients seeking gene-editing treatments.216 In this
context, these safeguards must also include clear guidelines regarding
who can serve as an appropriate surrogate decisionmaker when
potential participants have insufficient decisionmaking capacity.
In response to the lessons from history, regulatory bodies should
aim for clarity and uniformity in their rules. But absent government
action, the research community should nevertheless seek to take all
steps necessary to protect treatment-resistant patients who are highly
stigmatized and may lack decisionmaking capacity. These steps
should include the introduction of safeguards into informed consent
procedures and surrogate decisionmaking.
B.

General Ethical and Policy Issues Raised by CRISPR
Applications in Psychiatry
1. Extinction

Despite CRISPR’s therapeutic potential, technical issues
surrounding CRISPR systems raise ethical concerns, chief among
them being the potential for off-target effects.217 Off-target effects can
be thought of as unintended mutations that result from the CRISPR
intervention.218 Ethical concerns are especially poignant where the
off-target effects involve the unintended mutation of the germline,
meaning these unintended changes become heritable in humans.219
In theory, the CRISPR alterations discussed in this Article would
take place on somatic cells. A somatic cell modification is limited to
the progeny of the original cell that developed the mutation and is not
passable from parent to child.220 In contrast, a germline mutation is a
mutation to the cells from which eggs and sperm are derived and
through which genetic changes can be passed to the next
generation.221 Thus, unlike genome editing of human germline cells,
genome editing of human somatic cells aims to repair or eliminate
215. See supra Section I.C.
216. See supra Section I.C.
217. Xiang Jin Kang et al., Addressing Challenges in the Clinical Applications
Associated with CRISPR/Cas9 Technology and Ethical Questions to Prevent Its Misuse, 8
PROTEIN CELL 791, 792 (2017).
218. Id.
219. See id.
220. Kristine Krafts, Germline vs. Somatic Mutations, PATHOLOGY STUDENT (Aug. 22,
2013), http://www.pathologystudent.com/?p=8539 [https://perma.cc/75QD-EWL6].
221. Id.
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pathogenic variants that cause disease only in that particular
individual and not in his offspring.222
But perhaps the theoretically sharp distinction between germline
modification and somatic cell editing is somewhat idealistic. After all,
early gene-therapy trials often saw unintended consequences
impacting the germlines of research subjects, and early on, the FDA
called for extreme caution when enrolling fertile patients into gene
therapy studies.223 It is also possible that science may find a way to
intentionally alter the germline to eradicate targeted conditions from
future offspring. If this is in fact the case, CRISPR trials in psychiatry
do have the potential to affect future generations. Scientists must
consider the ethics of possibly eliminating genes associated with
psychiatric conditions from future offspring’s genetic profiles.
2. Legal History, Eugenics, and Psychiatry
Any discussion of extinction necessarily brings to mind the
eugenics movement that flourished in America and elsewhere during
the first part of the twentieth century and led to the implementation
of a number of state statutes authorizing the sterilization of people
affected by mental illness.224 Eugenics was founded on two core ideas:
(1) the presumed hereditary influence of mental illness and (2) that
people with mental illness had more children than the average
person.225 It’s important to remember that great thinkers of the time
saw eugenics as a legitimate and important public health movement,
endorsed by most scientists working in the field of human genetics.226
Ultimately, the effects of the eugenics movement on those with
psychiatric disorders reverberated throughout the world, as eugenics

222. Edward Lanphier et al., Don’t Edit the Human Germ Line, NATURE (Mar. 12,
2015), http://www.nature.com/news/don-t-edit-the-human-germ-line-1.17111 [https://perma.cc/
G8WA-53KC] (“The premise is that corrective changes to a sufficient number of cells
carrying the mutation—in which the genetic fixes would last the lifetimes of the modified
cells and their progeny—could provide a ‘one and done’ curative treatment for patients.”).
223. See Kang et al., supra note 217, at 792.
224. See, e.g., Act of Apr. 4, 1967, ch. 138, sec. 1, § 35-36, 1967 N.C. Sess. Laws 194, 194
(“[T]he State of North Carolina . . . is hereby authorized and directed to have the
necessary operation for asexualization or sterilization performed upon any mentally
defective or feeble-minded inmate of patient thereof . . . .”), repealed by Act of Apr. 7,
2003, ch. 13, § 1, 2003 N.C. Sess. Laws 11, 11.
225. Philip R. Reilly, Eugenics Ethics, Sterilization Laws, in 1 ENCYCLOPEDIA OF
ETHICAL, LEGAL, AND POLICY ISSUES IN BIOTECHNOLOGY 204, 205 (Thomas H. Murray
& Maxwell J. Mehlman eds., 2000).
226. ALLEN BUCHANAN ET AL., FROM CHANCE TO CHOICE: GENETICS AND JUSTICE
27–28 (2000).
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went on to form the core of Nazi doctrine.227 An estimated 300,000
people were sterilized under Hitler’s Germany.228 Most of those
targeted by sterilization laws were patients in mental health
hospitals.229 Additionally, throughout the United States, courts upheld
the constitutionality of states’ sterilization statutes, finding them
“justified by the findings of biological science.”230
But our legal system’s egregious treatment of those with
psychiatric conditions is not a thing of the past. Today, “[t]he
incidence of human rights violations in mental health care across
nations has been described as . . . an ‘unresolved global crisis.’”231 In
the United States over the last four decades, failed public policy,
targeted budget cuts, and economic crises have had a
disproportionate impact on those with serious psychiatric disorders.232
As a consequence, those with psychiatric disorders have been
relegated to an effective underclass, leaving those with untreated
conditions cycling through psychiatric hospitals, civil courts, criminal
courts, the streets, and correctional institutions.233
Recently, the United States Supreme Court commented on a
consequence of this subjugation in Brown v. Plata.234 In the case,
plaintiffs in two class actions alleged Eighth Amendment violations
based on the mistreatment of those affected by psychiatric disorders
in state correctional institutions.235 In a poignant opinion, the Court—
speaking through Justice Kennedy—ordered California to drastically
reduce its prison population.236 In doing so, Justice Kennedy noted
that suffering and death had resulted from the shortcomings in mental
health care and medical care for the mentally ill.237 Ironically

227. Id. at 28.
228. Forced Sterilizations, JEWISH VIRTUAL LIBR., https://www.jewishvirtuallibrary.org/
nazi-persecution-of-the-mentally-and-physically-disabled [https://perma.cc/6LWS-DAWX].
229. Id.
230. See, e.g., Smith v. Command, 204 N.W. 140, 142 (Mich. 1925).
231. Sebastian Porsdam Mann, Valerie J. Bradley & Barbara J. Sahakian, Human
Rights-Based Approaches to Mental Health, 18 HEALTH & HUM. RTS. J. 263, 263 (2016).
232. See ALISA ROTH, INSANE: AMERICA’S CRIMINAL TREATMENT OF MENTAL
ILLNESS 3 (2018) (“People with mental illness are among the most disadvantaged
members of our society, and when they end up in the criminal justice system, they tend to
fare worse than others.”).
233. See id. at 2.
234. 563 U.S. 493 (2011).
235. Id. at 499–500.
236. Id. at 504 (“A psychiatric expert reported observing an inmate who had been held
in such a cage for nearly 24 hours, standing in a pool of his own urine, unresponsive and
nearly catatonic. Prison officials explained they had ‘no place to put him.’”).
237. Id.
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California’s legislative response to the decree made no mention of
inmates with psychiatric disorders.238
3. Diversity
Keeping in mind eugenics’ shameful history, in contemplating
the use of CRISPR to treat psychiatric disorders, it is important to
stress that an optimal therapy would target the behavior an individual
has deemed disruptive and detrimental to his or her quality of life, as
opposed to a specific genetic profile. CRISPR gene-editing therapy
for an affected adult individual would not aim to eradicate a specific
trait entirely from a population. After all, the broader goal of genetic
cleansing would tread dangerously close to discrimination: the
distinction between diversity and disability is not always clear.239
With the completion of the Human Genome Project, scientists
had at their disposal a “map [of] the human genetic terrain”—a
standardized reference text.240 The purpose of genome sequencing
was to identify defective genes and correct genetic mistakes.241 But
the view of disability as a textual error—a “genetic other”—reinforces
a negative construction of disabilities and undervalues genetic
diversity.242 People without disabilities consistently underestimate the
life satisfaction of the disabled.243 In fact, the difference in quality of
life between the two groups is rather small, and a large proportion of
people with serious disabilities describe their quality of life
favorably.244 People also tend to overestimate how health impacts
happiness, giving health more weight than other factors, including

238. Anastasia Cooper, The Ongoing Correctional Chaos in Criminalizing Mental
Illness: The Realignment’s Effects on California Jails, 24 HASTINGS WOMEN’S L.J. 339, 341
(2013).
239. COMM. ON SCI., TECH., & LAW, NAT’L ACADS. OF SCIS., ENG’G, & MED.,
INTERNATIONAL SUMMIT ON HUMAN GENE EDITING: A GLOBAL DISCUSSION 4 (2015),
https://www.nap.edu/read/21913/chapter/1 [https://perma.cc/X5SU-PHWP].
240. See James C. Wilson, (Re)Writing the Genetic Body-Text: Disability, Textuality,
and the Human Genome Project, CULTURAL CRITIQUE, Winter 2002, at 23, 23.
241. Id. at 25.
242. Id. After all, this reference text is anything but diverse: it was derived from
samples of European origin. See id. at 26 (“Without [the Human Genome Diversity]
Project, science will characterize ‘the’ human genome, with its historical and medical
implications, largely in terms of what is known from a small sample of people of European
origin.”).
243. See Erika Check Hayden, Should You Edit Your Children’s Genes?, NATURE
(Feb. 23, 2016), http://www.nature.com/news/should-you-edit-your-children-s-genes-1.19432
[https://perma.cc/754M-5LXM].
244. See id. (“One study found that half of people with serious disabilities ranked their
quality of life as ‘good’ or ‘excellent.’”).
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economic stability or social support.245 Further, while in the United
States psychiatric disorders are considered pathological and viewed as
generally undesirable,246 the sentiment is not ubiquitous.247 Take for
example the Belgian town of Geel, where strangers with mental
illness have been embraced for centuries.248 In Geel, those with
psychiatric disorders are called guests or boarders, as opposed to
patients.249 Further, the attitudes of society shift over time as data is
gathered and synthesized, and it is possible that what we consider a
psychiatric disorder today may not be classified as such in the future.
After all, homosexuality was once, in the not-so-distant past,
categorized as a mental illness.250
The goal of eradicating a specific trait entirely from a population
also sounds a lot like the resurfacing of the eugenics movement.251
CRISPR technologies could be used to guide human evolution, which
was ultimately how some thinkers of the day conceptualized early
eugenics.252 It is true that once the genetic composition that results in
a phenotype is eradicated from within the individual’s germline cells,
he or she will no longer be capable of passing that trait onto his or her
offspring.253 For our purposes, however, the changes made in the
DNA of an individuals’ somatic cells would not be heritable.254 Geneediting therapies developed from the application of CRISPR

245. Id.
246. See Mary O’Hara, How the West Won Mental Health Thinking, GUARDIAN (Apr.
5, 2011), https://www.theguardian.com/society/2011/apr/05/west-foisting-mental-health-doctrinesworld [https://perma.cc/F264-8YBJ].
247. See, e.g., Angus Chen, For Centuries, a Small Town Has Embraced Strangers with
Mental Illness, NPR (July 1, 2016, 3:00 AM), http://www.npr.org/sections/health-shots/2016/
07/01/484083305/for-centuries-a-small-town-has-embraced-strangers-with-mental-illness
[https://perma.cc/B8FQ-ZQ26].
248. Id. (“[T]he extraordinary phenomenon presented at Geel of 400 insane persons
moving freely about in the midst of a population which tolerates them without fear and
without emotion.”).
249. Id.
250. See Neel Burton, When Homosexuality Stopped Being a Mental Disorder,
PSYCHOL. TODAY (Sept. 18, 2015), https://www.psychologytoday.com/blog/hide-andseek/201509/when-homosexuality-stopped-being-mental-disorder [https://perma.cc/EHN68H8X] (“Not until 1987 did homosexuality completely fall out of the DSM.”).
251. Paul Enríquez, Genome Editing and the Jurisprudence of Scientific Empiricism, 19
VAND. J. ENT. & TECH. L. 603, 670 (2017).
252. See Nathaniel Comfort, Can We Cure Genetic Diseases Without Slipping into
Eugenics?, NATION: BIOETHICS (July 16, 2015), https://www.thenation.com/article/can-wecure-genetic-diseases-without-slipping-into-eugenics/ [https://perma.cc/VS9M-JVMG].
253. See Tim Beck, CRISPR: The Future of Medicine and Human Evolution, INTRAINING (May 12, 2017), http://in-training.org/crispr-future-medicine-human-evolution13534 [https://perma.cc/AX7A-3N2P].
254. See Krafts, supra note 220.
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technologies are ultimately unlike the insidious negative eugenics
movement of our past in that the individual is free to reproduce and
continue on their unmodified genetic line.255 The focus of gene-editing
therapies, the individual’s genetic code, is different from the focus of
the eugenics movement—altering the composition of the population
at large.256 The former is focused on enhancing the well-being of an
individual.257 The latter was centered on the future of the human race
at the individual’s expense.258
CONCLUSION
Ample need exists for novel treatments in psychiatry, and
CRISPR is an attractive candidate as a future solution. Most
immediately, applications for treating monogenic diseases are likely.
And because of the speed at which these technologies are evolving,
coupled with the fact that CRISPR technologies are helping to
further unravel the genetic architecture of more complicated diseases,
additional applications in psychiatry are no longer highly improbable
hypotheticals. The use of gene-editing technologies in the delicate
realm of psychiatry, however, should take into consideration the harm
in society’s binary view of disability as abnormal. Science and
medicine, after all, are not value-free.259 And biomedical technologies
participate in translating social agendas into technological ones.260

255. Id.
256. See Comfort, supra note 252 (“Eugenics is ‘the self-direction of human
evolution.’”).
257. Matt Ridley, Foreword to DAVENPORT’S DREAM: 21ST CENTURY REFLECTIONS
ON HEREDITY AND EUGENICS, at ix, xi (Jan A. Witkowski & John R. Inglis eds., 2008)
(“One aims for individual happiness with no thought to the future of the human race; the
other aims to improve the race at the expense of individual happiness.”).
258. Id.
259. SANDRA HARDING, WHOSE SCIENCE? WHOSE KNOWLEDGE?: THINKING FROM
WOMEN’S LIVES 37 (1991) (“[T]he technologies used to produce scientific information are
not value-neutral. For example, the development of the telescope moved authority about
the patterns of the heavens from the church to the secular world and supported the
emerging importance of the authority of individual observation. Contemporary scientific
technologies . . . shift values in the sciences in other ways.”).
260. See id. at 37–38.

